PFIZER INC, 10-Q filed on 5/5/2026
Quarterly Report
v3.26.1
Cover Page - shares
 3 Months Ended
Mar. 29, 2026
Apr. 29, 2026
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 29, 2026  
Document Transition Report false  
Entity File Number 1-3619  
Entity Registrant Name PFIZER INC  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 13-5315170  
Entity Address, Address Line One 66 Hudson Boulevard East  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10001-2192  
City Area Code 212  
Local Phone Number 733-2323  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   5,699,444,169
Entity Central Index Key 0000078003  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Common Stock, $.05 par value [Member]    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, $0.05 par value  
Trading Symbol PFE  
Security Exchange Name NYSE  
1.000% Notes due 2027 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 1.000% Notes due 2027  
Trading Symbol PFE/27  
Security Exchange Name NYSE  
Notes Due 2029, 2.875% [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 2.875% Notes due 2029  
Trading Symbol PFE/29  
Security Exchange Name NYSE  
Notes Due 2032, 3.250% [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 3.250% Notes due 2032  
Trading Symbol PFE/32  
Security Exchange Name NYSE  
Notes Due 2037, 3.875% [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 3.875% Notes due 2037  
Trading Symbol PFE/37A  
Security Exchange Name NYSE  
Notes Due 2045, 4.250% [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 4.250% Notes due 2045  
Trading Symbol PFE/45  
Security Exchange Name NYSE  
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Alliance revenues $ 2,339 $ 2,113
Total revenues 14,451 13,715
Costs and expenses:    
Cost of sales [1] 3,548 2,845
Selling, informational and administrative expenses [1] 2,961 3,031
Research and development expenses [1] 2,490 2,203
Acquired in-process research and development expenses 137 9
Amortization of intangible assets 1,183 1,211
Restructuring charges and certain acquisition-related costs 100 678
Other (income)/deductions––net 861 953
Income from continuing operations before provision/(benefit) for taxes on income [2] 3,170 2,785
Provision/(benefit) for taxes on income 461 (189)
Income from continuing operations 2,709 2,973
Discontinued operations––net of tax (13) 0
Net income before allocation to noncontrolling interests 2,696 2,973
Less: Net income attributable to noncontrolling interests 8 6
Net income attributable to Pfizer Inc. common shareholders $ 2,687 $ 2,967
Earnings per common share––basic:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.48 $ 0.52
Discontinued operations––net of tax (in dollars per share) 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.47 0.52
Earnings per common share––diluted:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 0.47 0.52
Discontinued operations––net of tax (in dollars per share) 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.47 $ 0.52
Weighted-average shares--basic (in shares) 5,691 5,675
Weighted-average shares--diluted (in shares) 5,731 5,710
Product [Member]    
Revenues $ 11,715 $ 11,294
Royalty [Member]    
Revenues $ 396 $ 308
[1] Exclusive of amortization of intangible assets.
[2] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Statement of Comprehensive Income [Abstract]    
Net income before allocation to noncontrolling interests $ 2,696 $ 2,973
Foreign currency translation adjustments, net 923 (557)
Unrealized holding gains/(losses) on derivative financial instruments, net (36) (123)
Reclassification adjustments for (gains)/losses included in net income [1] 9 (313)
Other comprehensive income, cash flow hedge, gain (loss), before tax, total (27) (436)
Unrealized holding gains/(losses) on available-for-sale securities, net 38 (31)
Reclassification adjustments for (gains)/losses included in net income [2] 21 155
Other comprehensive income (loss), available-for-sale securities, before tax, total 60 124
Reclassification adjustments related to amortization of prior service costs and other, net (7) (30)
Reclassification adjustments related to curtailments of prior service costs and other, net (5) (33)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service costs and other, before tax (12) (64)
Other comprehensive income/(loss), before tax 944 (932)
Tax provision/(benefit) on other comprehensive income/(loss) 81 (191)
Other comprehensive income/(loss) before allocation to noncontrolling interests 863 (741)
Comprehensive income/(loss) before allocation to noncontrolling interests 3,559 2,232
Less: Comprehensive income/(loss) attributable to noncontrolling interests 5 4
Comprehensive income/(loss) attributable to Pfizer Inc. $ 3,554 $ 2,229
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] Reclassified into Other (income)/deductions—net.
v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Assets    
Cash and cash equivalents $ 1,703 $ 1,142
Short-term investments 11,372 12,454
Trade accounts receivable, net of allowance for doubtful accounts: 2026—$425; 2025—$427 12,585 11,874
Inventories 10,667 10,654
Current tax assets 3,588 3,967
Other current assets 2,908 2,808
Total current assets 42,822 42,898
Long-term investments 1,626 1,621
Property, plant and equipment, net of accumulated depreciation: 2026—$17,803; 2025—$17,386 19,402 19,317
Identifiable intangible assets, net 52,559 53,731
Goodwill 71,409 71,264
Noncurrent deferred tax assets and other noncurrent tax assets 9,965 9,699
Other noncurrent assets 9,834 9,631
Total assets 207,618 208,160
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2026—$3,861; 2025—$2,997 3,890 3,154
Trade accounts payable 4,506 5,240
Dividends payable 0 2,445
Income taxes payable 3,130 3,103
Accrued compensation and related items 2,715 3,610
Other current liabilities 20,108 19,432
Total current liabilities 34,348 36,984
Long-term debt 60,565 61,641
Pension and postretirement benefit obligations 1,984 2,041
Noncurrent deferred tax liabilities 2,412 2,401
Other taxes payable 3,705 3,591
Other noncurrent liabilities 14,200 14,725
Total liabilities 117,214 121,385
Commitments and Contingencies
Common stock 482 481
Additional paid-in capital 94,773 94,469
Treasury stock (115,190) (115,015)
Retained earnings 117,238 114,610
Accumulated other comprehensive loss (7,203) (8,069)
Total Pfizer Inc. shareholders’ equity 90,101 86,476
Equity attributable to noncontrolling interests 303 299
Total equity 90,404 86,775
Total liabilities and equity $ 207,618 $ 208,160
v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 425 $ 427
Property, plant and equipment, accumulated depreciation 17,803 17,386
Current portion of long-term debt $ 3,861 $ 2,997
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
Total
Shareholders' Equity [Member]
Common Stock [Member]
Add'l Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
Accum. Other Comp. Loss [Member]
Noncontrolling Interests [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (in shares)     9,593          
Beginning balance at Dec. 31, 2024 $ 88,497 $ 88,203 $ 480 $ 93,603 $ (114,763) $ 116,725 $ (7,842) $ 294
Beginning balance (in shares) at Dec. 31, 2024         (3,926)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 2,973 2,967       2,967   6
Other comprehensive income/(loss), net of tax (741) (738)         (738) (3)
Cash dividends declared:                
Common stock 0 0       0    
Share-based payment transactions (in shares)     27   9      
Share-based payment transactions (94) (94) $ 1 252 $ (245) (103)    
Other 2 1   0   1   2
Ending balance (in shares) at Mar. 30, 2025     9,620          
Ending balance at Mar. 30, 2025 90,637 90,338 $ 481 93,856 $ (115,008) 119,590 (8,581) 299
Ending balance (in shares) at Mar. 30, 2025         (3,935)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (in shares)     9,620          
Beginning balance (in shares)     9,621          
Beginning balance at Dec. 31, 2025 86,775 86,476 $ 481 94,469 $ (115,015) 114,610 (8,069) 299
Beginning balance (in shares) at Dec. 31, 2025         (3,935)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 2,696 2,687       2,687   8
Other comprehensive income/(loss), net of tax 863 867         867 [1] (4)
Cash dividends declared:                
Common stock 0 0       0    
Share-based payment transactions (in shares)     20   7      
Share-based payment transactions 70 70 $ 1 304 $ (176) (60)    
Other 1 1       1 0 0
Ending balance (in shares) at Mar. 29, 2026     9,641          
Ending balance at Mar. 29, 2026 $ 90,404 $ 90,101 $ 482 $ 94,773 $ (115,190) $ 117,238 $ (7,203) $ 303
Ending balance (in shares) at Mar. 29, 2026         (3,942)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (in shares)     9,641          
[1] Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL) - $ / shares
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Statement of Stockholders' Equity [Abstract]    
Cash dividends declared per share (in dollars per share) $ 0 $ 0
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Operating Activities    
Net income before allocation to noncontrolling interests $ 2,696 $ 2,973
Discontinued operations––net of tax (13) 0
Net income from continuing operations before allocation to noncontrolling interests 2,709 2,973
Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:    
Depreciation and amortization [1] 1,613 1,618
Asset write-offs and impairments 32 344
Deferred taxes (12) (663)
Share-based compensation expense 272 170
Benefit plan contributions in excess of expense/income (173) (229)
Other adjustments, net (93) 40
Other changes in assets and liabilities, net of acquisitions and divestitures (1,732) (1,919)
Net cash provided by/(used in) operating activities 2,615 2,335
Investing Activities    
Purchases of property, plant and equipment (436) (564)
Purchases of short-term investments (2,569) (2,823)
Proceeds from redemptions/sales of short-term investments 4,576 3,955
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less (792) (3,852)
Purchases of long-term investments (104) (134)
Proceeds from redemptions/sales of long-term investments 88 82
Proceeds from sales of investment in Haleon 0 6,311
Other investing activities, net 22 300
Net cash provided by/(used in) investing activities 785 3,274
Financing Activities    
Payments on short-term borrowings 0 (2,048)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less (127) (386)
Cash dividends paid (2,445) (2,437)
Other financing activities, net (284) (356)
Net cash provided by/(used in) financing activities (2,856) (5,227)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents 19 (7)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents 563 375
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period 1,197 1,107
Cash and cash equivalents and restricted cash and cash equivalents, at end of period 1,760 1,481
Cash paid during the period for:    
Income taxes 72 152
Interest paid 293 353
Interest rate hedges $ 62 $ 74
[1] Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.
v3.26.1
Basis of Presentation and Significant Accounting Policies
 3 Months Ended
Mar. 29, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2025 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2025 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 22, 2026 and February 23, 2025, and for U.S. subsidiaries is as of and for the three months ended March 29, 2026 and March 30, 2025.
We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and PC1. Biopharma is the only reportable segment. See Note 13A.
B. Revenues and Trade Accounts Receivable
Deductions from Revenues––Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)March 29,
2026		December 31, 2025
Reserve against Trade accounts receivable, net of allowance for doubtful accounts
$1,699 $1,803 
Other current liabilities:
Accrued rebates8,846 7,909 
Other accruals718 750 
Other noncurrent liabilities
287 1,204 
Total accrued rebates and other sales-related accruals$11,550 $11,666 
Trade Accounts Receivable––Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market, delinquency status, and customer type (high risk versus low risk and government versus non-government), and reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three months ended March 29, 2026 and March 30, 2025, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.
For additional information on our trade accounts receivable, see Note 1G in our 2025 Form 10-K.
v3.26.1
Acquisition, In-Licensing Arrangement and Sale of Investment
 3 Months Ended
Mar. 29, 2026
Research and Development [Abstract]  
Acquisition, In-Licensing Arrangement and Sale of Investment Acquisition, In-Licensing Arrangement and Sale of Investment
A. Acquisition
Metsera––On November 13, 2025, we acquired Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases, for $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share in potential additional payments (up to $2.3 billion) tied to the achievement of three specified milestones: $4.60 per share following the Phase 3 clinical trial start of Metsera’s injectable GLP-1 receptor antagonist MET-097i+amylin analog MET-233i combination, $6.40 per share following FDA approval of Metsera’s monthly MET-097i monotherapy and $9.65 per share following FDA approval of Metsera’s monthly MET-097i+MET-233i combination. The total fair value of the consideration transferred was $8.0 billion ($7.8 billion net of cash acquired), which includes the fair value of $632 million for the noncash CVRs and $475 million for employee stock awards related to pre-acquisition service.
In connection with this business combination, we provisionally recorded: (i) $8.0 billion of identifiable intangible assets, net, consisting of IPR&D, (ii) $2.0 billion of Goodwill, (iii) $1.6 billion of net deferred tax liabilities, and (iv) $672 million of contingent consideration liability assumed from Metsera. Goodwill, which resulted primarily from the recognition of deferred tax liabilities, is related to our Biopharma segment and is not deductible for tax purposes. The contingent consideration liability was recorded at fair value and relates to Metsera’s 2023 acquisition of Zihipp Ltd (Zihipp). As a part of that transaction, the former Zihipp shareholders are entitled to future potential development, regulatory and commercialization milestone payments, along with low-single digit royalties on net product sales on the MET-097i and MET-233i product candidates. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
B. In-Licensing Arrangement
In-Licensing Arrangement with Sciwind Biosciences––In February 2026, Pfizer and Sciwind Biosciences announced a strategic commercialization collaboration in which Pfizer obtained exclusive commercialization rights for Sciwind Biosciences’ glucagon-like peptide 1 (GLP-1) receptor agonist ecnoglutide in Mainland China. Sciwind Biosciences remains the Marketing Authorization Holder and is responsible for R&D, registration, manufacturing and supply of the product. Sciwind Biosciences is eligible to receive an aggregate of up to $495 million in upfront, regulatory and sales milestone payments.
C. Sale of Investment
ViiV––On March 31, 2026, which fell in our second fiscal quarter of 2026, Pfizer completed the exit of its 11.7% investment in ViiV (carrying value of zero) and received $1.875 billion in cash proceeds. See Note 2C in our 2025 Form 10-K.
v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
 3 Months Ended
Mar. 29, 2026
Restructuring and Related Activities [Abstract]  
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Realigning Our Cost Base Program
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. In the second quarter of 2025, we identified additional productivity opportunities to further reduce costs primarily in SI&A, driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes.
We expect costs associated with these components of the program to be incurred through 2027 and to total approximately $4.7 billion, representing primarily cash expenditures for severance, implementation, exit, and digital enablement costs, as well as non-cash asset write downs of which $3.1 billion is associated with our Biopharma segment.
Additionally, in connection with our efforts to simplify the structure and sharpen the focus of our R&D organization, in the first quarter of 2025, we expanded this program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The majority of these costs were recorded in 2025, with cash outlays expected primarily through 2026.
We expect costs associated with all the components of this program to total approximately $5.3 billion of which $3.7 billion is associated with the Biopharma segment.
From the start of this program through March 29, 2026, we incurred total costs of $4.3 billion, of which $3.3 billion is associated with our Biopharma segment (including $2.9 billion of restructuring charges).
B. Manufacturing Optimization Program
In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which includes operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is primarily focused on operational efficiencies, and we expect costs for this first phase to total approximately $1.4 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. From the start of this program through March 29, 2026, we incurred costs of $1.1 billion (including $853 million of restructuring charges). These costs were recorded primarily through 2025, with cash outlays expected primarily through 2026.
C. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Restructuring charges/(credits):  
Employee terminations$15 $384 
Asset impairments28 173 
Exit costs
6 64 
Restructuring charges/(credits)(a)
49 621 
Integration costs and other(b)
51 57 
Restructuring charges and certain acquisition-related costs100 678 
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net
3 (59)
Additional depreciation––asset restructuring recorded in Cost of sales(c)
3 4 
Implementation costs recorded in our condensed consolidated statements of operations as follows(d):
  
Cost of sales15 20 
Selling, informational and administrative expenses36 6 
Research and development expenses38 24 
Total implementation costs89 50 
Total costs associated with acquisitions and cost-reduction/productivity initiatives$195 $673 
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
(b)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(c)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(d)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
Costs		Asset
Impairment
Charges		Exit CostsAccrual
Balance, December 31, 2025(a)
$1,783 $— $127 $1,910 
Provision
15 28 6 49 
Utilization and other(b)
(330)(28)(12)(371)
Balance, March 29, 2026(c)
$1,467 $— $121 $1,588 
(a)Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)Included in Other current liabilities ($1.2 billion) and Other noncurrent liabilities ($431 million).
v3.26.1
Other (Income)/Deductions—Net
 3 Months Ended
Mar. 29, 2026
Other Income and Expenses [Abstract]  
Other (Income)/Deductions—Net Other (Income)/Deductions—Net
Components of Other (income)/deductions––net include:
 Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Interest income$(115)$(143)
Interest expense668 654 
Net interest expense
554 511 
Net (gains)/losses recognized during the period on equity securities
9 370 
Net periodic benefit costs/(credits) other than service costs(72)(158)
Certain legal matters, net(a)
191 142 
Certain asset impairments(b)
— 224 
Changes in fair value of contingent consideration liabilities(c)
295 8 
Other, net
(116)(144)
Other (income)/deductions––net
$861 $953 
(a)The amount for the first quarter of 2026 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2025 included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(b)The amount for the first quarter of 2025 primarily represented an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
(c)See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.
v3.26.1
Tax Matters
 3 Months Ended
Mar. 29, 2026
Income Tax Disclosure [Abstract]  
Tax Matters Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was 14.6% for the first quarter of 2026, compared to (6.8)% for the first quarter of 2025. The increase in the effective tax rate for the first quarter of 2026, compared to the first quarter of 2025, was primarily due to an unfavorable change in the jurisdictional mix of earnings, and non-recurrence of favorable global income tax resolutions.
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The eighth and final annual installment was paid by its April 15, 2026 due date and was reported in current Income taxes payable as of March 29, 2026. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.
See Note 5A in our 2025 Form 10-K for information on our income taxes paid (net of refunds received).
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2019-2022 are under audit. Tax years 2023-2026 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2016.
See Note 5D in our 2025 Form 10-K.
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Foreign currency translation adjustments, net(a)
$76 $(102)
Unrealized holding gains/(losses) on derivative financial instruments, net(5)(34)
Reclassification adjustments for (gains)/losses included in net income
6 (55)
— (89)
Unrealized holding gains/(losses) on available-for-sale securities, net5 (4)
Reclassification adjustments for (gains)/losses included in net income
3 19 
7 15 
Reclassification adjustments related to amortization of prior service costs and other, net(2)(7)
Reclassification adjustments related to curtailments of prior service costs and other, net(1)(9)
(3)(16)
Tax provision/(benefit) on other comprehensive income/(loss)
$81 $(191)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
v3.26.1
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
 3 Months Ended
Mar. 29, 2026
Equity [Abstract]  
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
 Net Unrealized Gains/(Losses)Benefit Plans 
(MILLIONS)
Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2026
$(7,796)$(321)$(28)$75 $(8,069)
Other comprehensive income/(loss)(b)
851 (27)52 (9)867 
Balance, March 29, 2026$(6,944)$(348)$24 $66 $(7,203)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.
v3.26.1
Financial Instruments
 3 Months Ended
Mar. 29, 2026
Fair Value Disclosures [Abstract]  
Financial Instruments Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy:
March 29, 2026December 31, 2025
(MILLIONS)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$1,865 $— $1,865 $— $2,596 $— $2,596 $— 
Available-for-sale debt securities:
Government and agency—non-U.S.
3,888 — 3,888 — 4,859 — 4,859 — 
Government and agency—U.S.
2,935 — 2,935 — 3,030 — 3,030 — 
Corporate and other
1,366 — 1,366 — 1,294 — 1,294 — 
8,189 — 8,189 — 9,183 — 9,183 — 
Total short-term investments10,054 — 10,054 — 11,779 — 11,779 — 
Other current assets
Derivative assets:
Interest rate contracts
6 — 6 — — — — — 
Foreign exchange contracts
498 — 498 — 416 — 416 — 
Total other current assets504 — 504 — 416 — 416 — 
Long-term investments
Equity securities with readily determinable fair values(b)
653 653 — — 642 642 — — 
Available-for-sale debt securities:
Government and agency—non-U.S.
— — — — 1 — 1 — 
Corporate and other
— — — — — — — — 
— — — — 1 — 1 — 
Total long-term investments653 653 — — 642 642 1 — 
Other noncurrent assets
Derivative assets:
Interest rate contracts
27 — 27 — 52 — 52 — 
Foreign exchange contracts
128 — 128 — 64 — 64 — 
Total derivative assets155 — 155 — 116 — 116 — 
Insurance contracts(c)
950 — 950 — 999 — 999 — 
Total other noncurrent assets1,105 — 1,105 — 1,115 — 1,115 — 
Total assets$12,315 $653 $11,663 $— $13,953 $642 $13,311 $— 
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$1 $— $1 $— $16 $— $16 $— 
Foreign exchange contracts
283 — 283 — 412 — 412 — 
Contingent consideration liabilities(d)
95 — — 95 95 — — 95 
Total other current liabilities379 — 284 95 523 — 428 95 
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts275 — 275 — 215 — 215 — 
Foreign exchange contracts
807 — 807 — 815 — 815 — 
Contingent consideration liabilities(d)
1,946 — — 1,946 1,695 — — 1,695 
Total other noncurrent liabilities3,027 — 1,081 1,946 2,725 — 1,030 1,695 
Total liabilities$3,406 $— $1,365 $2,041 $3,248 $— $1,458 $1,790 
(a)Includes money market funds primarily invested in U.S. Treasury and government debt.
(b)Long-term equity securities of $147 million as of March 29, 2026 and $146 million as of December 31, 2025 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).
(d)Includes the fair value of contingent consideration associated with the acquisition of Metsera and certain prior business combinations. Fair value is estimated by using a probability-weighted discounted cash flow approach (see Notes 1D and 16D in our 2025 Form 10-K and Note 2A for additional information on contingent consideration liabilities).
The following provides the changes in our contingent consideration liabilities valued using significant unobservable inputs:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Fair value, beginning$1,790 $517 
Changes in estimated fair value(a)
295 8 
Additions— — 
Settlements and other
(45)(48)
Transfer into/(out of) Level 3— — 
Fair value, ending$2,041 $477 
(a)Reported in Other (income)/deductions––net. See Note 4. The amount in the first quarter of 2026 is primarily related to our acquisition of Metsera.
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis––The carrying value of Long-term debt, excluding the current portion, was $61 billion as of March 29, 2026 and $62 billion as of December 31, 2025. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $58 billion as of March 29, 2026 and $60 billion as of December 31, 2025.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of March 29, 2026 and December 31, 2025. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term and Long-Term Investments
The following summarizes our investments by classification type:
(MILLIONS)March 29,
2026		 December 31, 2025
Short-term investments
Equity securities with readily determinable fair values
$1,865 $2,596 
Available-for-sale debt securities8,189 9,183 
Held-to-maturity debt securities1,318 675 
Total Short-term investments$11,372 $12,454 
Long-term investments
Equity securities with readily determinable fair values(a)
$653 $642 
Available-for-sale debt securities— 1 
Held-to-maturity debt securities47 48 
Private equity securities at cost(a)
688 696 
Equity-method investments237 235 
Total Long-term investments$1,626 $1,621 
(a)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
March 29, 2026December 31, 2025
Gross Unrealized
 Maturities (in Years)
Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5		Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$3,860 $29 $(2)$3,888 $3,888 $— $— $4,890 $3 $(34)$4,859 
Government and agency––U.S.
2,935 — — 2,935 2,935 — — 3,030 — — 3,030 
Corporate and other1,366 — — 1,366 1,366 — — 1,295 — (1)1,294 
Held-to-maturity debt securities
Corporate, time deposits and other
756 — — 756 710 9 37 487 — — 487 
Government and agency––non-U.S.
610 — — 610 608 — 1 236 — — 236 
Total debt securities$9,526 $29 $(2)$9,554 $9,507 $10 $38 $9,938 $3 $(35)$9,906 
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Net (gains)/losses recognized during the period on equity securities(a)
$9 $370 
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(6)(924)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date
$15 $1,295 
(a)Reported in Other (income)/deductions––net. See Note 4.
Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of March 29, 2026, there were cumulative impairments and downward adjustments of $444 million and upward adjustments of $225 million. Impairments, downward and upward adjustments were not material to our operations in the first quarters of 2026 and 2025.
C. Short-Term Borrowings
Short-term borrowings include:
(MILLIONS) March 29,
2026		 December 31, 2025
Current portion of long-term debt, principal amount$3,864 $3,000 
Other short-term borrowings, principal amount(a)
29 157 
Total short-term borrowings, principal amount
3,893 3,157 
Net unamortized discounts, premiums and debt issuance costs(3)(3)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$3,890 $3,154 
(a)Primarily includes cash collateral. See Note 7F.
D. Long-Term Debt
The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:
(MILLIONS)March 29,
2026		 December 31, 2025
Total long-term debt, principal amount$60,313 $61,293 
Net fair value adjustments related to hedging and purchase accounting726 834 
Net unamortized discounts, premiums and debt issuance costs(473)(486)
Total long-term debt, carried at historical proceeds, as adjusted$60,565 $61,641 
E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk––A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Chinese renminbi, Japanese yen, Canadian dollar, and Swedish krona, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may also seek to protect against possible declines in the net investments of our foreign business entities.
Interest Rate Risk––Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest
rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.
The following summarizes the fair value of the derivative financial instruments and notional amounts:
March 29, 2026December 31, 2025
Fair ValueFair Value
(MILLIONS)NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,593 $517 $942 $22,984 $325 $1,066 
Interest rate contracts7,995 33 276 6,750 52 230 
550 1,218 377 1,296 
Derivatives not designated as hedging instruments:
Foreign exchange contracts$17,134 109 147 $22,777 155 162 
Total$659 $1,365 $532 $1,458 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of March 29, 2026 and $5.0 billion as of December 31, 2025.
The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:
 
Gains/(Losses)
Recognized in OID(a)
Gains/(Losses)
Recognized in OCI(a)
Gains/(Losses)
Reclassified from
OCI into OID and COS(a)
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025
Derivative Financial Instruments in Cash Flow Hedge Relationships:
Interest rate contracts$— $— $— $— $— $2 
Foreign exchange contracts(b)
— — (48)(138)(21)295 
Amount excluded from effectiveness testing and amortized into earnings(c)
— — 12 15 12 16 
Derivative Financial Instruments in Fair Value Hedge Relationships:
Interest rate contracts(85)142 — — — — 
Hedged item 85 (142)— — — — 
Derivative Financial Instruments in Net Investment Hedge Relationships:      
Foreign exchange contracts— — 240 (437)— — 
Amount excluded from effectiveness testing and amortized into earnings(c)
— — 47 75 53 41 
Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d):
      
Foreign currency short-term borrowings— — 18 — — — 
Foreign currency long-term debt— — (2)(31)— — 
Derivative Financial Instruments Not Designated as Hedges:
Foreign exchange contracts(13)(31)— — — — 
 $(13)$(31)$267 $(517)$44 $354 
(a)OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income/(loss).
(b)The amounts reclassified from OCI into COS were a net loss of $14 million in the first quarter of 2026 and a net gain of $62 million in the first quarter of 2025. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $9 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 17 years and relates to foreign currency debt.
(c)The amounts reclassified from OCI were reclassified into OID.
(d)Long-term debt includes foreign currency borrowings, which are used in net investment hedges; the related carrying values as of March 29, 2026 and December 31, 2025 were $863 million and $879 million, respectively.
The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:
March 29, 2026December 31, 2025
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount		Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount
(MILLIONS)
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Long-term debt$8,429 $(248)$803 $7,110 $(163)$821 
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
F. Credit Risk
A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see Note 17C in our 2025 Form 10-K.
As of March 29, 2026, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., the U.K., France, Sweden, and Japan.
With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of March 29, 2026, the aggregate fair value of these derivative financial instruments that are in a net payable position was $1.1 billion, for which we have posted collateral of $1.2 billion with a corresponding amount reported in Short-term investments. As of March 29, 2026, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $41 million, for which we have received collateral of $29 million with a corresponding amount reported in Short-term borrowings, including current portion of long-term debt.
v3.26.1
Other Financial Information
 3 Months Ended
Mar. 29, 2026
Other Financial Information [Abstract]  
Other Financial Information Other Financial Information
A. Inventories
The following summarizes the components of Inventories:
(MILLIONS)March 29,
2026		December 31, 2025
Finished goods$4,031 $4,113 
Work-in-process5,713 5,634 
Raw materials and supplies923 907 
Inventories
$10,667 $10,654 
Noncurrent inventories not included above(a)
$2,462 $2,370 
(a)Included in Other noncurrent assets. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
B. Supplier Finance Program Obligation
We maintain voluntary supply chain finance agreements with several participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Pfizer to these financial institutions. As of March 29, 2026 and December 31, 2025, respectively, $518 million and $574 million of our trade payables to suppliers who participate in these financing arrangements were outstanding.
v3.26.1
Identifiable Intangible Assets, Net and Goodwill
 3 Months Ended
Mar. 29, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Identifiable Intangible Assets, Net and Goodwill Identifiable Intangible Assets, Net and Goodwill
A. Identifiable Intangible Assets
The following summarizes the components of Identifiable intangible assets:
March 29, 2026December 31, 2025
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$101,396 $(71,491)$29,905 $100,630 $(70,172)$30,458 
Brands1,035 (1,035)— 1,035 (1,035)— 
Licensing agreements and other2,350 (1,336)1,013 2,341 (1,289)1,052 
104,780 (73,862)30,918 104,006 (72,496)31,510 
Indefinite-lived intangible assets
IPR&D(a)
21,180 21,180 21,760 21,760 
Licensing agreements and other
460 460 460 460 
21,641 21,641 22,221 22,221 
Identifiable intangible assets
$126,421 $(73,862)$52,559 $126,227 $(72,496)$53,731 
(a)The gross carrying amounts reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).
B. Goodwill
As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2026 (see Note 13A), our goodwill is required to be reallocated amongst impacted reporting units. The reallocation of goodwill is a complex process that requires, among other things, determination of the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. The reallocation will be completed in the current fiscal year. All goodwill continues to be assigned within the Biopharma reportable segment.
v3.26.1
Pension and Postretirement Benefit Plans
 3 Months Ended
Mar. 29, 2026
Retirement Benefits [Abstract]  
Pension and Postretirement Benefit Plans Pension and Postretirement Benefit Plans
The following summarizes the components of net periodic benefit cost/(credit):
 Pension Plans
 U.S.InternationalPostretirement
Plans
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025
Service cost$— $— $24 $24 $4 $4 
Interest cost127 133 75 70 7 6 
Expected return on plan assets(188)(184)(82)(79)(16)(14)
Amortization of prior service cost/(credit)— — 1 1 (8)(32)
Actuarial (gains)/losses
— — 8 — — — 
Curtailments— — 3 (9)(5)(50)
Special termination benefits— — 5 — — — 
Net periodic benefit cost/(credit) reported in income$(60)$(51)$34 $8 $(18)$(85)
The components of net periodic benefit cost/(credit) other than the service cost component are primarily included in Other (income)/deductions––net (see Note 4).
For the three months ended March 29, 2026, we contributed $63 million to our U.S. Pension Plans and $68 million to our International Pension Plans from our general assets, which include direct employer benefit payments.
v3.26.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
 3 Months Ended
Mar. 29, 2026
Earnings Per Share [Abstract]  
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
The following presents the detailed calculation of EPS:
 Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
EPS Numerator
Income from continuing operations attributable to Pfizer Inc. common shareholders$2,701 $2,967 
Discontinued operations––net of tax(13)— 
Net income attributable to Pfizer Inc. common shareholders$2,687 $2,967 
EPS Denominator  
Weighted-average number of common shares outstanding––Basic5,691 5,675 
Common-share equivalents40 36 
Weighted-average number of common shares outstanding––Diluted5,731 5,710 
Anti-dilutive common stock equivalents(a)
11 17 
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
v3.26.1
Contingencies and Certain Commitments
 3 Months Ended
Mar. 29, 2026
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and Certain Commitments Contingencies and Certain Commitments
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and indemnifications. The following outlines our legal contingencies, guarantees and indemnifications. For a discussion of our tax contingencies, see Note 5B.
A. Legal Proceedings
Our legal contingencies include, but are not limited to, the following:
•Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions.
•Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.
•Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.
•Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.
Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges.
We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a
governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.
The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.
A1. Legal Proceedings––Patent Litigation
We are involved in suits relating to our patents (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights), including but not limited to, those discussed below. We face claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026, and this judgment is now final. Additional challenges are pending in other jurisdictions. Adverse decisions in these matters could have a material adverse effect on our results of operations. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payors, governments or other parties are seeking damages from us for allegedly causing delay of generic entry.
We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, as well as court proceedings relating to our intellectual property or the intellectual property rights of others, including challenges to such rights initiated by us. Also, if one of our patents (or one of our collaboration/licensing partner’s patents) is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office, as well as outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor’s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.
We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. If one of our marketed products (or a product of our collaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.
Actions In Which We Are The Plaintiff
Vyndaqel-Vyndamax (tafamidis/tafamidis meglumine)
Beginning in June 2023, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of tafamidis capsules (61 mg) or tafamidis meglumine capsules (20 mg), challenging some or all of the patents listed in the FDA’s Orange Book for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine). Scripps Research Institute (Scripps) owns the composition of matter patent and the method of treatment patents covering the products, and Pfizer is the exclusive licensee. Pfizer separately owns the crystalline form patent. Beginning in August 2023, we and Scripps brought
patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents in suit. Pfizer is the sole plaintiff in actions that assert only the infringement and validity of the crystalline form patent. In March 2026, we settled the case involving Vyndaqel on terms not material to the Company. In April 2026, we settled three cases involving Vyndamax. Under the terms of the settlements, the generic companies will be permitted to launch generic versions of Vyndamax capsules on June 1, 2031, subject to the outcome of other litigation relating to Vyndamax. An additional patent infringement action involving Apotex Corp. relating to Vyndamax is ongoing in the U.S. District Court for the District of Delaware.
Oxbryta (voxelotor)
In January 2024, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, and Zydus Worldwide DMCC (collectively, Zydus) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd. (collectively, MSN) separately notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of voxelotor tablets, challenging some of the patents listed in the FDA’s Orange Book for Oxbryta (voxelotor tablets in 300 mg and 500 mg strengths and/or for oral suspension) on non-infringement grounds. In March 2024, we filed patent infringement actions against both generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the challenged patents. Zydus and MSN have not challenged our composition of matter patents or method of treatment patents for Oxbryta.
Nurtec (rimegepant)
In April 2024, Rubicon Research Private Limited, Teva Pharmaceuticals, Inc., Changzhou Pharmaceutical Factory, Natco Pharma Limited and Natco Pharma, Inc., MSN, Aurobindo Pharma Limited, Apitoria Pharma Private Limited and Aurobindo Pharma U.S.A. Inc. (collectively, Aurobindo) and Apotex Inc. and Apotex Corp. (collectively, Apotex) notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of rimegepant orally disintegrating tablets, claiming noninfringement and/or challenging the validity of some or all of the patents listed in the FDA’s Orange Book for Nurtec (rimegepant orally disintegrating tablets Eq 75 mg base). In May 2024, we filed patent infringement actions against all the generic filers in the U.S. District Court for the District of Delaware.
Xtandi (enzalutamide)
Beginning in August 2024, several generic companies notified us and Astellas that they had filed ANDAs with the FDA seeking approval to market generic versions of Xtandi, challenging some or all of the patents listed in the FDA’s Orange Book for Xtandi. Beginning in August 2024, we and Astellas brought patent infringement actions against the generic filers in the U.S. District Court for the District of New Jersey, asserting the validity and infringement of the patents in suit.
Cibinqo (abrocitinib)
In March 2026, Micro Labs Limited and Micro Labs USA, Inc. (collectively, Micro Labs), Changzhou Pharmaceutical Factory (Changzhou), and Biocon Limited, Biocon Pharma Limited and Biocon Pharma, Inc. (collectively, Biocon) notified us that they filed ANDAs with the FDA seeking approval to market generic versions of abrocitinib and challenging all three patents listed in the Orange Book. In April 2026, we filed patent infringement actions against Micro Labs, Changzhou and Biocon in the U.S. District Court for the District of Delaware asserting the infringement and validity of the challenged patents.
Actions in Which We are the Defendant
Comirnaty (tozinameran)
In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In March 2024, the U.S. Patent Office Patent Trial & Appeal Board instituted a review of two of the three patents in suit. In March 2025, the U.S. Patent Office issued a decision holding that the two Moderna patents were invalid.
In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes two European patents. In March 2025, a German court found the asserted patents infringed; no decision on invalidity was rendered. In September 2022, ModernaTX filed patent infringement actions in the U.K. and in the Netherlands against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, on the same two European patents. In its complaints, ModernaTX stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In November 2023, one of the European patents was revoked by the European Patent Office and, in January 2026, that decision became final. In December 2023, the other European patent was declared invalid by a court in the Netherlands (the invalidity decision is limited to the Netherlands). In July 2024, the U.K. court revoked one patent, ruling that it was invalid, and held that the other patent was valid and infringed. In July 2025, the U.K. Court of Appeal affirmed the lower court ruling that the other patent is valid and infringed. ModernaTX has also filed additional patent infringement actions against Pfizer and BioNTech in certain other ex-U.S. jurisdictions.
In April 2023, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech alleging that Comirnaty and its manufacture infringe five U.S. patents, and seeking unspecified monetary damages.
In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC (collectively, GSK Group) sued Pfizer and Pharmacia & Upjohn Company LLC, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Delaware, alleging that Comirnaty infringes five U.S. patents and seeking unspecified money damages. In August 2024, GSK Group filed an amended complaint alleging that Comirnaty infringes three additional U.S. patents. In July 2025, GSK Group sued several Pfizer and BioNTech entities in Ireland, alleging that Comirnaty infringes three European patents. Also in July 2025, GSK Group sued several Pfizer and BioNTech entities in the Unified Patent Court, alleging that Comirnaty infringes two European patents, both of which are at issue in the Irish lawsuit. Additional patent infringement actions between GSK Group and Pfizer/BioNTech are ongoing in certain other ex-U.S. jurisdictions.
In January 2025, Promosome LLC filed a complaint in the Unified Patent Court, Local Division Munich, against Pfizer and BioNTech and certain of their subsidiaries alleging that Comirnaty infringes a European patent that is in force only in France, Germany and Sweden, and seeking unspecified monetary damages in connection with the manufacture and sale of Comirnaty in France, Germany and Sweden.
In January 2026, Bayer Cropscience LLC, Monsanto Company and Monsanto Technology, LLC filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc, alleging that Comirnaty infringes a U.S. patent issued in 2010 and seeking unspecified money damages.
Paxlovid
In June 2022, Enanta Pharmaceuticals, Inc. (Enanta) filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes a U.S. patent issued in June 2022, and seeking unspecified monetary damages. In December 2024, the District Court issued an order granting Pfizer’s motion for summary judgment, finding Enanta’s patent invalid.
In August 2025, Enanta filed a patent infringement complaint in the Unified Patent Court, Local Division Munich, against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes a European patent issued in August 2025, and seeking unspecified monetary damages.
Matters Involving Pfizer and its Collaboration/Licensing Partners
Orgovyx (relugolix)
Beginning in January 2025, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to sell a generic form of relugolix (Orgovyx), and challenging one or more patents listed in the FDA’s Orange Book for Orgovyx which are licensed to Pfizer. In March 2025, we, along with Sumitomo Pharma Switzerland GBBH, Sumitomo Pharma America, Inc., Takeda and Takeda Pharmaceuticals International AG jointly filed separate patent infringement actions in the U.S. District Court for the District of Delaware against the generic companies, asserting the infringement and validity of the patents in suit.
Eliquis (apixaban)
In December 2025, BMS and Pfizer filed a patent infringement action in the U.S. District Court for the District of Delaware against Azurity Pharmaceuticals, Inc. (Azurity), alleging that Azurity’s proposed generic apixaban product would infringe a formulation patent expiring in 2031.
A2. Legal Proceedings––Product Litigation
We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.
Asbestos
Numerous lawsuits against Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.
In addition, between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.
There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.
Docetaxel
A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. Hospira is a wholly-owned subsidiary that we acquired in September 2015. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.
In 2016, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Eastern District of Louisiana. All of the hair loss and eye injury cases filed against Hospira and Pfizer have been dismissed with prejudice.
Zantac
A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson & Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson & Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.
In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of Florida (the Federal MDL Court). Plaintiffs in the MDL filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In December 2022, the Federal MDL Court granted defendants’ Daubert motions to exclude plaintiffs’ expert testimony and motion for summary judgment on general causation, which has resulted in the dismissal of all complaints in the litigation. Plaintiffs have appealed the Federal MDL Court’s rulings.
In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions. In April 2026, the Company reached agreements with the State of New Mexico and the Mayor and City Council of Baltimore on terms not material to Pfizer. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts. The large majority of the state court cases have been filed in the Superior Court of Delaware in New Castle County.
Many of these Zantac-related cases have been outstanding for a number of years. From time to time, Pfizer has explored and will continue to explore opportunistic settlements of these matters. As of May 2026, Pfizer had settled, or entered into definitive agreements or agreements-in-principle to settle, subject to certain conditions, a substantial majority of the cases filed in state courts in which the plaintiff alleges use of a Pfizer product. The remaining unresolved state court cases continue in various state courts.
Chantix
Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer’s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. In December 2022, the federal actions were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Southern District of New York. In March 2026, the parties reached an agreement in principle to resolve the litigation on terms not material to Pfizer. The agreement is subject to court approval.
Depo-Provera
A number of lawsuits have been filed against Pfizer and certain subsidiaries in various federal and state courts alleging that plaintiffs who used the injectable version of Depo-Provera (active ingredient medroxyprogesterone acetate, or MPA) for contraception developed meningioma. Some cases also name other defendants, including the manufacturers of generic versions
of injectable MPA for contraception. Plaintiffs assert claims against Pfizer relating to both Depo-Provera and generic MPA products, and seek compensatory and punitive damages. In February 2025, the federal cases were transferred for coordinated pre-trial proceedings to an MDL in the U.S. District Court for the Northern District of Florida. Also, in 2025, coordinated proceedings were established in several U.S. state jurisdictions, including California, Connecticut, Delaware, and New York.
A3. Legal Proceedings––Commercial and Other Matters
Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.
In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.
In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation. In 2018, Bayer AG acquired Monsanto Company (New Monsanto), which is now a subsidiary of Bayer AG. Since the acquisition, New Monsanto has continued to defend and indemnify Pharmacia for these liabilities.
Environmental Matters
In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency, the New Jersey Department of Environmental Protection and/or federal and state natural resource trustees to perform remedial design, removal and remedial actions, and related environmental remediation activities, and to resolve alleged damages to natural resources, at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.
We are also party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.
Contracts with Iraqi Ministry of Health
In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health and seeks monetary relief. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of plaintiffs’ claims. In January 2022, the Court of Appeals reversed the District Court’s decision. In June 2024, the U.S. Supreme Court issued an order granting certiorari, vacating the Court of Appeals’ decision, and remanding the case to the Court of Appeals. In January 2026, the Court of Appeals reversed the District Court’s decision and, in February 2026, the defendants filed a petition seeking reconsideration by the Court of Appeals, which was denied.
Allergan Complaint for Indemnity
In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period
by King in 2008, prior to Pfizer’s acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.
Breach of Contract – Comirnaty
In 2023, Pfizer and BioNTech Manufacturing GmbH initiated separate formal proceedings against the Republic of Poland, the Republic of Romania and Hungary in Belgium’s Court of First Instance of Brussels, seeking to hold those countries to their commitments for COVID-19 vaccine orders, which were placed as part of their contracts signed in 2021. In April 2026, the Court of First Instance of Brussels issued a judgment in favor of Pfizer and BioNTech against the Republic of Poland and the Republic of Romania. The proceedings against Hungary are continuing separately.
A4. Legal Proceedings––Government Investigations
Like other multi-national pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.
Greenstone Antitrust Litigation
In 2019 and 2020, Attorneys General of more than 50 states and territories filed two complaints in the U.S. District Court for the District of Connecticut against a number of pharmaceutical companies, including Pfizer and Greenstone—a former Pfizer subsidiary that sold generic drugs. As to Greenstone and Pfizer, the complaints allege anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. The State Attorney General complaints were initially transferred to an MDL in the U.S. District Court for the Eastern District of Pennsylvania for coordinated pre-trial proceedings but were transferred back to the District of Connecticut in April 2024. The Greenstone antitrust litigation also includes civil complaints filed in federal and state court by private and governmental plaintiffs against Pfizer, Greenstone, and a number of other defendants. These related civil lawsuits assert allegations that generally overlap with those asserted by the State Attorneys General. All of the related federal lawsuits are part of the MDL pending in Pennsylvania.
U.S. Department of Justice Inquiries relating to India Operations
In March 2020, we received an informal request from the U.S. Department of Justice’s Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney’s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We have produced records pursuant to these requests.
Zantac––State of New Mexico and Mayor and City Council of Baltimore Civil Actions
See Legal Proceedings––Product Litigation––Zantac above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions.
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 29, 2026, the estimated fair value of these indemnification obligations is not material to Pfizer.
In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.
See Note 7D in our 2025 Form 10-K for information on Pfizer Inc.’s guarantee of the debt issued by Pfizer Netherlands International Finance B.V. (a wholly-owned finance subsidiary of Pfizer) in May 2025 and the debt issued by Pfizer Investment
Enterprises Pte. Ltd. (a wholly-owned finance subsidiary of Pfizer) in May 2023. We have also guaranteed the long-term debt of certain subsidiaries of Pfizer and certain companies that we acquired and that now are subsidiaries of Pfizer.
C. Contingent Consideration for Acquisitions
We may be required to make contingent consideration payments to sellers for certain prior Pfizer business combinations that are contingent on future events or outcomes. We also have assumed certain contingent consideration liabilities that were previously promised to sellers by a company subsequently acquired by Pfizer. See Notes 1D and 16D in our 2025 Form 10-K and Notes 2A and 7A.
v3.26.1
Segment, Geographic and Other Revenue Information
 3 Months Ended
Mar. 29, 2026
Segment Reporting [Abstract]  
Segment, Geographic and Other Revenue Information Segment, Geographic and Other Revenue Information
A. Segment Information
Beginning in the first quarter of 2026, we manage our commercial operations through two operating segments, each led by a single manager: Biopharma and PC1. This structure reflects our current operating model following the wind-down in 2025 of the Pfizer Ignite operating segment. Biopharma is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is the only reportable segment. We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources.
Within our Biopharma reportable segment, our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. Each operating segment is supported by our global corporate enabling functions and other corporate functions. At the beginning of 2026, we made changes in our commercial organization, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Global Hospital and Biosimilars Division within our Biopharma reportable segment to support our continued focus on commercial execution. Effective January 1, 2026, the commercial structure within our Biopharma reportable segment is as follows:
•Pfizer U.S. Commercial Division includes the U.S. commercial organization covering Pfizer’s entire product portfolio except for the Global Hospital and Biosimilars organization, as well as the Global Access & Value, Global Chief Marketing Office and Primary Care and Specialty Care U.S. Medical Affairs organizations.
•Pfizer International Commercial Division includes the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets except for the Global Hospital and Biosimilars organization in certain international markets.
•Global Hospital and Biosimilars Division includes the commercial organization covering Pfizer’s Hospital and Biosimilars product portfolio of off-patent branded and generic sterile injectables and biosimilars except in China, Hong Kong, and certain other international markets, which are part of the Pfizer International Commercial Division.
Other Business Activities and Reconciling Items––Other business activities include the operating results of PC1 and our former operating segment, Pfizer Ignite, as well as certain pre-tax costs not allocated to our operating segment results, such as costs associated with corporate enabling functions and other corporate costs. Reconciling items include the following items, transactions and events that are not allocated to our operating segments: (i) all amortization of intangible assets; (ii) acquisition-related items; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Segment Assets––We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $208 billion as of March 29, 2026 and $208 billion as of December 31, 2025.
Selected Statement of Operations Information
The following provides selected information by reportable segment:
Three Months Ended
 
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
(MILLIONS)March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025
Reportable Segment:
Biopharma(c)
$14,161 $13,441 $6,838 $7,069 $348 $331 
Other business activities(d)
289 273 (1,668)(1,384)78 74 
Reconciling Items:
Amortization of intangible assets(1,183)(1,211)1,183 1,211 
Acquisition-related items(504)(282)— (1)
Certain significant items(e)
(312)(1,407)3 4 
$14,451 $13,715 $3,170 $2,785 $1,613 $1,618 
(a)Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.
(c)Biopharma’s earnings include dividend income from our investment in ViiV of $82 million in the first quarter of 2026 and $39 million in the first quarter of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the first quarter of 2025 also reflected a credit to Cost of Sales representing a favorable revision of our estimate of accrued royalties.
(d)Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.
(e)Earnings in the first quarter of 2025 included, among other items restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $666 million (primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 3.
The following provides Biopharma reportable segment information regularly provided to the CODM:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Biopharma reportable segment:
Biopharma total revenues$14,161 $13,441 
Less:
Cost of sales3,034 2,314 
Selling, informational and administrative expenses2,131 2,186 
Research and development expenses2,137 1,941 
Acquired in-process research and development expenses137 9 
Other (income)/deductions––net(116)(78)
Biopharma earnings$6,838 $7,069 
B. Geographic Information
The following summarizes revenues by geographic area:
 Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
United States$8,731 $8,374 
International:
Developed Markets
3,426 3,178 
Emerging Markets2,293 2,163 
Total revenues
$14,451 $13,715 
C. Other Revenue Information
Significant Revenues by Product
The following provides detailed revenue information for several of our major products:
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSMarch 29,
2026		March 30,
2025
TOTAL REVENUES$14,451 $13,715 
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a)
$14,161 $13,441 
Primary Care$5,542 $5,692 
Eliquis(b)
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism2,166 1,923 
Prevnar family
Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae
1,690 1,660 
Nurtec ODT/VyduraAcute treatment of migraine and prevention of episodic migraine353 248 
ComirnatyActive immunization to prevent COVID-19232 565 
Paxlovid
COVID-19 in certain high-risk patients186 491 
Abrysvo
Active immunization to prevent RSV infection
180 131 
FSME-IMMUN/TicoVacActive immunization to prevent tick-borne encephalitis disease81 63 
All other Primary CareVarious654 609 
Oncology$3,826 $3,494 
IbranceHR-positive/HER2-negative metastatic breast cancer1,008 977 
Padcev
Locally advanced or metastatic urothelial cancer and cisplatin-ineligible/decline muscle invasive bladder cancer (MIBC)
591 426 
Xtandi(c)
mCRPC, nmCRPC, mCSPC, nmCSPC444 458 
LorbrenaALK-positive metastatic NSCLC305 222 
Inlyta
Advanced renal cell carcinoma
214 219 
Adcetris(d)
Certain lymphomas including classical Hodgkin lymphoma, T-cell lymphoma and relapsed/refractory diffuse large B-cell lymphoma
190 218 
Braftovi/Mektovi
Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux® (cetuximab)(e) (after prior therapy) or cetuximab and fluorouracil-based chemotherapy
174 136 
BosulifPhiladelphia chromosome–positive chronic myelogenous leukemia129 151 
Tukysa
Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer122 102 
Orgovyx(f)
Advanced prostate cancer
109 76 
Elrexfio
Relapsed or refractory multiple myeloma
80 60 
Talzenna
Treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer; and, in combination with Xtandi (enzalutamide), of adult patients with HRR gene-mutated mCRPC
50 40 
Tivdak
Recurrent or mCC with disease progression on or after chemotherapy
33 33 
All other Oncology
Various376 377 
Specialty Care$2,939 $2,616 
Vyndaqel familyATTR-CM and polyneuropathy1,602 1,486 
XeljanzRA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis180 128 
Zavicefta (Outside the U.S. and Canada)
Bacterial infections150 135 
Enbrel (Outside the U.S. and Canada)RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis138 140 
Octagam
Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults
122 88 
GenotropinReplacement of human growth hormone93 95 
CibinqoAtopic dermatitis76 58 
All other Specialty CareVarious579 486 
Hospital and Biosimilars(a)
$1,854 $1,639 
Oncology biosimilars(g)
Various
409 264 
Sulperazon (Outside the U.S. and Canada)
Bacterial infections199 164 
InflectraCrohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis182 153 
ZithromaxBacterial infections112 158 
All other Hospital and Biosimilars
Various
953 901 
PFIZER CENTREONE(h)
$289 $273 
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSMarch 29,
2026		March 30,
2025
BIOPHARMA(a)
$14,161 $13,441 
PFIZER U.S. COMMERCIAL DIVISION
7,686 7,572 
PFIZER INTERNATIONAL COMMERCIAL DIVISION
5,233 4,849 
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(i)
1,242 1,020 
Total Alliance revenues included above$2,339 $2,113 
Total Royalty revenues included above
$396 $308 
(a)In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation.
(b)Reflects alliance revenues and royalty revenues.
(c)Primarily reflects alliance revenues and royalty revenues.
(d)Reflects product revenues and royalty revenues.
(e)Erbitux® is a registered trademark of ImClone LLC.
(f)Reflects alliance revenues.
(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Zirabev, Retacrit, Trazimera and Nivestym.
(h)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in both periods presented. We reclassified prior period amounts to conform to the current period presentation.
(i)See Note 13A above.
Remaining Performance Obligations––Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty and Paxlovid to our customers totaled approximately $2.1 billion and $948 million, respectively, as of March 29, 2026, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of these amounts, current contract terms provide for expected delivery of product with contracted revenue primarily from 2026 through 2028, the timing of which may be renegotiated. Remaining performance obligations are based on foreign exchange rates as of the end of our fiscal first quarter of 2026 and exclude arrangements with an original expected contract duration of less than one year. Remaining performance obligations associated with contracts for other products and services were not significant as of March 29, 2026 or December 31, 2025.
Deferred Revenues––Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers for supply of Paxlovid and Comirnaty. The deferred revenues related to Paxlovid and Comirnaty totaled $1.5 billion as of March 29, 2026, with $646 million and $816 million recorded in current liabilities and noncurrent liabilities, respectively. The deferred revenues related to Paxlovid and Comirnaty totaled $1.5 billion as of December 31, 2025, with $689 million and $826 million recorded in current liabilities and noncurrent liabilities, respectively. The activity in Paxlovid and Comirnaty deferred revenues during the first three months of 2026 was primarily amounts recognized in Product revenues as we delivered the products to our customers. During the first quarter of 2026, we recognized revenue of approximately $58 million that was included in the balance of Comirnaty and Paxlovid deferred revenues as of December 31, 2025. The Paxlovid and Comirnaty deferred revenues as of March 29, 2026 will be recognized in Product revenues proportionately as we transfer control of the products to our customers and satisfy our performance obligations under the contracts, with the amounts included in current liabilities expected to be recognized in Product revenues within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in Product revenues primarily from 2027 through 2028. Deferred revenues associated with contracts for other products were not significant as of March 29, 2026 or December 31, 2025.
v3.26.1
Insider Trading Arrangements
 3 Months Ended
Mar. 29, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.1
Basis of Presentation and Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 29, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2025 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2025 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 22, 2026 and February 23, 2025, and for U.S. subsidiaries is as of and for the three months ended March 29, 2026 and March 30, 2025.
Trade Accounts Receivable
Trade Accounts Receivable––Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market, delinquency status, and customer type (high risk versus low risk and government versus non-government), and reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
v3.26.1
Basis of Presentation and Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 29, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Balance Sheet Classification of Accruals
Deductions from Revenues––Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)March 29,
2026		December 31, 2025
Reserve against Trade accounts receivable, net of allowance for doubtful accounts
$1,699 $1,803 
Other current liabilities:
Accrued rebates8,846 7,909 
Other accruals718 750 
Other noncurrent liabilities
287 1,204 
Total accrued rebates and other sales-related accruals$11,550 $11,666 
v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)
 3 Months Ended
Mar. 29, 2026
Restructuring and Related Activities [Abstract]  
Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Restructuring charges/(credits):  
Employee terminations$15 $384 
Asset impairments28 173 
Exit costs
6 64 
Restructuring charges/(credits)(a)
49 621 
Integration costs and other(b)
51 57 
Restructuring charges and certain acquisition-related costs100 678 
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net
3 (59)
Additional depreciation––asset restructuring recorded in Cost of sales(c)
3 4 
Implementation costs recorded in our condensed consolidated statements of operations as follows(d):
  
Cost of sales15 20 
Selling, informational and administrative expenses36 6 
Research and development expenses38 24 
Total implementation costs89 50 
Total costs associated with acquisitions and cost-reduction/productivity initiatives$195 $673 
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
(b)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(c)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(d)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components and Changes in Restructuring Accruals
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
Costs		Asset
Impairment
Charges		Exit CostsAccrual
Balance, December 31, 2025(a)
$1,783 $— $127 $1,910 
Provision
15 28 6 49 
Utilization and other(b)
(330)(28)(12)(371)
Balance, March 29, 2026(c)
$1,467 $— $121 $1,588 
(a)Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)Included in Other current liabilities ($1.2 billion) and Other noncurrent liabilities ($431 million).
v3.26.1
Other (Income)/Deductions—Net (Tables)
 3 Months Ended
Mar. 29, 2026
Other Income and Expenses [Abstract]  
Schedule of Other (Income)/Deductions - Net
Components of Other (income)/deductions––net include:
 Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Interest income$(115)$(143)
Interest expense668 654 
Net interest expense
554 511 
Net (gains)/losses recognized during the period on equity securities
9 370 
Net periodic benefit costs/(credits) other than service costs(72)(158)
Certain legal matters, net(a)
191 142 
Certain asset impairments(b)
— 224 
Changes in fair value of contingent consideration liabilities(c)
295 8 
Other, net
(116)(144)
Other (income)/deductions––net
$861 $953 
(a)The amount for the first quarter of 2026 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2025 included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(b)The amount for the first quarter of 2025 primarily represented an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
(c)See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.
v3.26.1
Tax Matters (Tables)
 3 Months Ended
Mar. 29, 2026
Income Tax Disclosure [Abstract]  
Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Foreign currency translation adjustments, net(a)
$76 $(102)
Unrealized holding gains/(losses) on derivative financial instruments, net(5)(34)
Reclassification adjustments for (gains)/losses included in net income
6 (55)
— (89)
Unrealized holding gains/(losses) on available-for-sale securities, net5 (4)
Reclassification adjustments for (gains)/losses included in net income
3 19 
7 15 
Reclassification adjustments related to amortization of prior service costs and other, net(2)(7)
Reclassification adjustments related to curtailments of prior service costs and other, net(1)(9)
(3)(16)
Tax provision/(benefit) on other comprehensive income/(loss)
$81 $(191)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
v3.26.1
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)
 3 Months Ended
Mar. 29, 2026
Equity [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Loss
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
 Net Unrealized Gains/(Losses)Benefit Plans 
(MILLIONS)
Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2026
$(7,796)$(321)$(28)$75 $(8,069)
Other comprehensive income/(loss)(b)
851 (27)52 (9)867 
Balance, March 29, 2026$(6,944)$(348)$24 $66 $(7,203)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.
v3.26.1
Financial Instruments (Tables)
 3 Months Ended
Mar. 29, 2026
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy:
March 29, 2026December 31, 2025
(MILLIONS)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$1,865 $— $1,865 $— $2,596 $— $2,596 $— 
Available-for-sale debt securities:
Government and agency—non-U.S.
3,888 — 3,888 — 4,859 — 4,859 — 
Government and agency—U.S.
2,935 — 2,935 — 3,030 — 3,030 — 
Corporate and other
1,366 — 1,366 — 1,294 — 1,294 — 
8,189 — 8,189 — 9,183 — 9,183 — 
Total short-term investments10,054 — 10,054 — 11,779 — 11,779 — 
Other current assets
Derivative assets:
Interest rate contracts
6 — 6 — — — — — 
Foreign exchange contracts
498 — 498 — 416 — 416 — 
Total other current assets504 — 504 — 416 — 416 — 
Long-term investments
Equity securities with readily determinable fair values(b)
653 653 — — 642 642 — — 
Available-for-sale debt securities:
Government and agency—non-U.S.
— — — — 1 — 1 — 
Corporate and other
— — — — — — — — 
— — — — 1 — 1 — 
Total long-term investments653 653 — — 642 642 1 — 
Other noncurrent assets
Derivative assets:
Interest rate contracts
27 — 27 — 52 — 52 — 
Foreign exchange contracts
128 — 128 — 64 — 64 — 
Total derivative assets155 — 155 — 116 — 116 — 
Insurance contracts(c)
950 — 950 — 999 — 999 — 
Total other noncurrent assets1,105 — 1,105 — 1,115 — 1,115 — 
Total assets$12,315 $653 $11,663 $— $13,953 $642 $13,311 $— 
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$1 $— $1 $— $16 $— $16 $— 
Foreign exchange contracts
283 — 283 — 412 — 412 — 
Contingent consideration liabilities(d)
95 — — 95 95 — — 95 
Total other current liabilities379 — 284 95 523 — 428 95 
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts275 — 275 — 215 — 215 — 
Foreign exchange contracts
807 — 807 — 815 — 815 — 
Contingent consideration liabilities(d)
1,946 — — 1,946 1,695 — — 1,695 
Total other noncurrent liabilities3,027 — 1,081 1,946 2,725 — 1,030 1,695 
Total liabilities$3,406 $— $1,365 $2,041 $3,248 $— $1,458 $1,790 
(a)Includes money market funds primarily invested in U.S. Treasury and government debt.
(b)Long-term equity securities of $147 million as of March 29, 2026 and $146 million as of December 31, 2025 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).
(d)Includes the fair value of contingent consideration associated with the acquisition of Metsera and certain prior business combinations. Fair value is estimated by using a probability-weighted discounted cash flow approach (see Notes 1D and 16D in our 2025 Form 10-K and Note 2A for additional information on contingent consideration liabilities).
Schedule of Changes in Contingent Consideration Liabilities
The following provides the changes in our contingent consideration liabilities valued using significant unobservable inputs:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Fair value, beginning$1,790 $517 
Changes in estimated fair value(a)
295 8 
Additions— — 
Settlements and other
(45)(48)
Transfer into/(out of) Level 3— — 
Fair value, ending$2,041 $477 
(a)Reported in Other (income)/deductions––net. See Note 4. The amount in the first quarter of 2026 is primarily related to our acquisition of Metsera.
Investments by Classification Type
The following summarizes our investments by classification type:
(MILLIONS)March 29,
2026		 December 31, 2025
Short-term investments
Equity securities with readily determinable fair values
$1,865 $2,596 
Available-for-sale debt securities8,189 9,183 
Held-to-maturity debt securities1,318 675 
Total Short-term investments$11,372 $12,454 
Long-term investments
Equity securities with readily determinable fair values(a)
$653 $642 
Available-for-sale debt securities— 1 
Held-to-maturity debt securities47 48 
Private equity securities at cost(a)
688 696 
Equity-method investments237 235 
Total Long-term investments$1,626 $1,621 
(a)Represent investments in the life sciences sector.
Schedule of Held-to-maturity Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
March 29, 2026December 31, 2025
Gross Unrealized
 Maturities (in Years)
Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5		Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$3,860 $29 $(2)$3,888 $3,888 $— $— $4,890 $3 $(34)$4,859 
Government and agency––U.S.
2,935 — — 2,935 2,935 — — 3,030 — — 3,030 
Corporate and other1,366 — — 1,366 1,366 — — 1,295 — (1)1,294 
Held-to-maturity debt securities
Corporate, time deposits and other
756 — — 756 710 9 37 487 — — 487 
Government and agency––non-U.S.
610 — — 610 608 — 1 236 — — 236 
Total debt securities$9,526 $29 $(2)$9,554 $9,507 $10 $38 $9,938 $3 $(35)$9,906 
Schedule of Available-for-sale Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
March 29, 2026December 31, 2025
Gross Unrealized
 Maturities (in Years)
Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5		Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$3,860 $29 $(2)$3,888 $3,888 $— $— $4,890 $3 $(34)$4,859 
Government and agency––U.S.
2,935 — — 2,935 2,935 — — 3,030 — — 3,030 
Corporate and other1,366 — — 1,366 1,366 — — 1,295 — (1)1,294 
Held-to-maturity debt securities
Corporate, time deposits and other
756 — — 756 710 9 37 487 — — 487 
Government and agency––non-U.S.
610 — — 610 608 — 1 236 — — 236 
Total debt securities$9,526 $29 $(2)$9,554 $9,507 $10 $38 $9,938 $3 $(35)$9,906 
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
March 29, 2026December 31, 2025
Gross Unrealized
 Maturities (in Years)
Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5		Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency––non-U.S.
$3,860 $29 $(2)$3,888 $3,888 $— $— $4,890 $3 $(34)$4,859 
Government and agency––U.S.
2,935 — — 2,935 2,935 — — 3,030 — — 3,030 
Corporate and other1,366 — — 1,366 1,366 — — 1,295 — (1)1,294 
Held-to-maturity debt securities
Corporate, time deposits and other
756 — — 756 710 9 37 487 — — 487 
Government and agency––non-U.S.
610 — — 610 608 — 1 236 — — 236 
Total debt securities$9,526 $29 $(2)$9,554 $9,507 $10 $38 $9,938 $3 $(35)$9,906 
Schedule of Gains and Losses on Investment Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Net (gains)/losses recognized during the period on equity securities(a)
$9 $370 
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(6)(924)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date
$15 $1,295 
(a)Reported in Other (income)/deductions––net. See Note 4.
Schedule of Short-term Borrowings
Short-term borrowings include:
(MILLIONS) March 29,
2026		 December 31, 2025
Current portion of long-term debt, principal amount$3,864 $3,000 
Other short-term borrowings, principal amount(a)
29 157 
Total short-term borrowings, principal amount
3,893 3,157 
Net unamortized discounts, premiums and debt issuance costs(3)(3)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$3,890 $3,154 
(a)Primarily includes cash collateral. See Note 7F.
Schedule of Senior Unsecured Notes Issued, Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments
The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:
(MILLIONS)March 29,
2026		 December 31, 2025
Total long-term debt, principal amount$60,313 $61,293 
Net fair value adjustments related to hedging and purchase accounting726 834 
Net unamortized discounts, premiums and debt issuance costs(473)(486)
Total long-term debt, carried at historical proceeds, as adjusted$60,565 $61,641 
Schedule of Derivative Instruments
The following summarizes the fair value of the derivative financial instruments and notional amounts:
March 29, 2026December 31, 2025
Fair ValueFair Value
(MILLIONS)NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,593 $517 $942 $22,984 $325 $1,066 
Interest rate contracts7,995 33 276 6,750 52 230 
550 1,218 377 1,296 
Derivatives not designated as hedging instruments:
Foreign exchange contracts$17,134 109 147 $22,777 155 162 
Total$659 $1,365 $532 $1,458 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of March 29, 2026 and $5.0 billion as of December 31, 2025.
Schedule of Derivative Assets
The following summarizes the fair value of the derivative financial instruments and notional amounts:
March 29, 2026December 31, 2025
Fair ValueFair Value
(MILLIONS)NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,593 $517 $942 $22,984 $325 $1,066 
Interest rate contracts7,995 33 276 6,750 52 230 
550 1,218 377 1,296 
Derivatives not designated as hedging instruments:
Foreign exchange contracts$17,134 109 147 $22,777 155 162 
Total$659 $1,365 $532 $1,458 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of March 29, 2026 and $5.0 billion as of December 31, 2025.
Schedule of Derivative Liabilities
The following summarizes the fair value of the derivative financial instruments and notional amounts:
March 29, 2026December 31, 2025
Fair ValueFair Value
(MILLIONS)NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,593 $517 $942 $22,984 $325 $1,066 
Interest rate contracts7,995 33 276 6,750 52 230 
550 1,218 377 1,296 
Derivatives not designated as hedging instruments:
Foreign exchange contracts$17,134 109 147 $22,777 155 162 
Total$659 $1,365 $532 $1,458 
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of March 29, 2026 and $5.0 billion as of December 31, 2025.
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk
The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:
 
Gains/(Losses)
Recognized in OID(a)
Gains/(Losses)
Recognized in OCI(a)
Gains/(Losses)
Reclassified from
OCI into OID and COS(a)
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025
Derivative Financial Instruments in Cash Flow Hedge Relationships:
Interest rate contracts$— $— $— $— $— $2 
Foreign exchange contracts(b)
— — (48)(138)(21)295 
Amount excluded from effectiveness testing and amortized into earnings(c)
— — 12 15 12 16 
Derivative Financial Instruments in Fair Value Hedge Relationships:
Interest rate contracts(85)142 — — — — 
Hedged item 85 (142)— — — — 
Derivative Financial Instruments in Net Investment Hedge Relationships:      
Foreign exchange contracts— — 240 (437)— — 
Amount excluded from effectiveness testing and amortized into earnings(c)
— — 47 75 53 41 
Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d):
      
Foreign currency short-term borrowings— — 18 — — — 
Foreign currency long-term debt— — (2)(31)— — 
Derivative Financial Instruments Not Designated as Hedges:
Foreign exchange contracts(13)(31)— — — — 
 $(13)$(31)$267 $(517)$44 $354 
(a)OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income/(loss).
(b)The amounts reclassified from OCI into COS were a net loss of $14 million in the first quarter of 2026 and a net gain of $62 million in the first quarter of 2025. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $9 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 17 years and relates to foreign currency debt.
(c)The amounts reclassified from OCI were reclassified into OID.
(d)Long-term debt includes foreign currency borrowings, which are used in net investment hedges; the related carrying values as of March 29, 2026 and December 31, 2025 were $863 million and $879 million, respectively.
Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded
The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:
March 29, 2026December 31, 2025
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount		Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to
Carrying Amount
(MILLIONS)
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Carrying Amount of Hedged Assets/Liabilities(a)
Active Hedging RelationshipsDiscontinued Hedging Relationships
Long-term debt$8,429 $(248)$803 $7,110 $(163)$821 
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
v3.26.1
Other Financial Information (Tables)
 3 Months Ended
Mar. 29, 2026
Other Financial Information [Abstract]  
Schedule of Components of Inventories, Current
The following summarizes the components of Inventories:
(MILLIONS)March 29,
2026		December 31, 2025
Finished goods$4,031 $4,113 
Work-in-process5,713 5,634 
Raw materials and supplies923 907 
Inventories
$10,667 $10,654 
Noncurrent inventories not included above(a)
$2,462 $2,370 
(a)Included in Other noncurrent assets. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
Schedule of Components of Inventories, Noncurrent
The following summarizes the components of Inventories:
(MILLIONS)March 29,
2026		December 31, 2025
Finished goods$4,031 $4,113 
Work-in-process5,713 5,634 
Raw materials and supplies923 907 
Inventories
$10,667 $10,654 
Noncurrent inventories not included above(a)
$2,462 $2,370 
(a)Included in Other noncurrent assets. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
v3.26.1
Identifiable Intangible Assets, Net and Goodwill (Tables)
 3 Months Ended
Mar. 29, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
March 29, 2026December 31, 2025
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$101,396 $(71,491)$29,905 $100,630 $(70,172)$30,458 
Brands1,035 (1,035)— 1,035 (1,035)— 
Licensing agreements and other2,350 (1,336)1,013 2,341 (1,289)1,052 
104,780 (73,862)30,918 104,006 (72,496)31,510 
Indefinite-lived intangible assets
IPR&D(a)
21,180 21,180 21,760 21,760 
Licensing agreements and other
460 460 460 460 
21,641 21,641 22,221 22,221 
Identifiable intangible assets
$126,421 $(73,862)$52,559 $126,227 $(72,496)$53,731 
(a)The gross carrying amounts reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).
Schedule of Indefinite Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
March 29, 2026December 31, 2025
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$101,396 $(71,491)$29,905 $100,630 $(70,172)$30,458 
Brands1,035 (1,035)— 1,035 (1,035)— 
Licensing agreements and other2,350 (1,336)1,013 2,341 (1,289)1,052 
104,780 (73,862)30,918 104,006 (72,496)31,510 
Indefinite-lived intangible assets
IPR&D(a)
21,180 21,180 21,760 21,760 
Licensing agreements and other
460 460 460 460 
21,641 21,641 22,221 22,221 
Identifiable intangible assets
$126,421 $(73,862)$52,559 $126,227 $(72,496)$53,731 
(a)The gross carrying amounts reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).
v3.26.1
Pension and Postretirement Benefit Plans (Tables)
 3 Months Ended
Mar. 29, 2026
Retirement Benefits [Abstract]  
Schedule of Net Periodic Benefit Costs
The following summarizes the components of net periodic benefit cost/(credit):
 Pension Plans
 U.S.InternationalPostretirement
Plans
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025
Service cost$— $— $24 $24 $4 $4 
Interest cost127 133 75 70 7 6 
Expected return on plan assets(188)(184)(82)(79)(16)(14)
Amortization of prior service cost/(credit)— — 1 1 (8)(32)
Actuarial (gains)/losses
— — 8 — — — 
Curtailments— — 3 (9)(5)(50)
Special termination benefits— — 5 — — — 
Net periodic benefit cost/(credit) reported in income$(60)$(51)$34 $8 $(18)$(85)
v3.26.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)
 3 Months Ended
Mar. 29, 2026
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Share
The following presents the detailed calculation of EPS:
 Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
EPS Numerator
Income from continuing operations attributable to Pfizer Inc. common shareholders$2,701 $2,967 
Discontinued operations––net of tax(13)— 
Net income attributable to Pfizer Inc. common shareholders$2,687 $2,967 
EPS Denominator  
Weighted-average number of common shares outstanding––Basic5,691 5,675 
Common-share equivalents40 36 
Weighted-average number of common shares outstanding––Diluted5,731 5,710 
Anti-dilutive common stock equivalents(a)
11 17 
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
v3.26.1
Segment, Geographic and Other Revenue Information (Tables)
 3 Months Ended
Mar. 29, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
The following provides selected information by reportable segment:
Three Months Ended
 
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
(MILLIONS)March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025		March 29,
2026		March 30,
2025
Reportable Segment:
Biopharma(c)
$14,161 $13,441 $6,838 $7,069 $348 $331 
Other business activities(d)
289 273 (1,668)(1,384)78 74 
Reconciling Items:
Amortization of intangible assets(1,183)(1,211)1,183 1,211 
Acquisition-related items(504)(282)— (1)
Certain significant items(e)
(312)(1,407)3 4 
$14,451 $13,715 $3,170 $2,785 $1,613 $1,618 
(a)Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.
(c)Biopharma’s earnings include dividend income from our investment in ViiV of $82 million in the first quarter of 2026 and $39 million in the first quarter of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the first quarter of 2025 also reflected a credit to Cost of Sales representing a favorable revision of our estimate of accrued royalties.
(d)Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.
(e)Earnings in the first quarter of 2025 included, among other items restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $666 million (primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 3.
The following provides Biopharma reportable segment information regularly provided to the CODM:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Biopharma reportable segment:
Biopharma total revenues$14,161 $13,441 
Less:
Cost of sales3,034 2,314 
Selling, informational and administrative expenses2,131 2,186 
Research and development expenses2,137 1,941 
Acquired in-process research and development expenses137 9 
Other (income)/deductions––net(116)(78)
Biopharma earnings$6,838 $7,069 
Schedule of Revenues by Geographic Region
The following summarizes revenues by geographic area:
 Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
United States$8,731 $8,374 
International:
Developed Markets
3,426 3,178 
Emerging Markets2,293 2,163 
Total revenues
$14,451 $13,715 
Schedule of Significant Product Revenues
The following provides detailed revenue information for several of our major products:
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSMarch 29,
2026		March 30,
2025
TOTAL REVENUES$14,451 $13,715 
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a)
$14,161 $13,441 
Primary Care$5,542 $5,692 
Eliquis(b)
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism2,166 1,923 
Prevnar family
Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae
1,690 1,660 
Nurtec ODT/VyduraAcute treatment of migraine and prevention of episodic migraine353 248 
ComirnatyActive immunization to prevent COVID-19232 565 
Paxlovid
COVID-19 in certain high-risk patients186 491 
Abrysvo
Active immunization to prevent RSV infection
180 131 
FSME-IMMUN/TicoVacActive immunization to prevent tick-borne encephalitis disease81 63 
All other Primary CareVarious654 609 
Oncology$3,826 $3,494 
IbranceHR-positive/HER2-negative metastatic breast cancer1,008 977 
Padcev
Locally advanced or metastatic urothelial cancer and cisplatin-ineligible/decline muscle invasive bladder cancer (MIBC)
591 426 
Xtandi(c)
mCRPC, nmCRPC, mCSPC, nmCSPC444 458 
LorbrenaALK-positive metastatic NSCLC305 222 
Inlyta
Advanced renal cell carcinoma
214 219 
Adcetris(d)
Certain lymphomas including classical Hodgkin lymphoma, T-cell lymphoma and relapsed/refractory diffuse large B-cell lymphoma
190 218 
Braftovi/Mektovi
Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux® (cetuximab)(e) (after prior therapy) or cetuximab and fluorouracil-based chemotherapy
174 136 
BosulifPhiladelphia chromosome–positive chronic myelogenous leukemia129 151 
Tukysa
Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer122 102 
Orgovyx(f)
Advanced prostate cancer
109 76 
Elrexfio
Relapsed or refractory multiple myeloma
80 60 
Talzenna
Treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer; and, in combination with Xtandi (enzalutamide), of adult patients with HRR gene-mutated mCRPC
50 40 
Tivdak
Recurrent or mCC with disease progression on or after chemotherapy
33 33 
All other Oncology
Various376 377 
Specialty Care$2,939 $2,616 
Vyndaqel familyATTR-CM and polyneuropathy1,602 1,486 
XeljanzRA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis180 128 
Zavicefta (Outside the U.S. and Canada)
Bacterial infections150 135 
Enbrel (Outside the U.S. and Canada)RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis138 140 
Octagam
Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults
122 88 
GenotropinReplacement of human growth hormone93 95 
CibinqoAtopic dermatitis76 58 
All other Specialty CareVarious579 486 
Hospital and Biosimilars(a)
$1,854 $1,639 
Oncology biosimilars(g)
Various
409 264 
Sulperazon (Outside the U.S. and Canada)
Bacterial infections199 164 
InflectraCrohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis182 153 
ZithromaxBacterial infections112 158 
All other Hospital and Biosimilars
Various
953 901 
PFIZER CENTREONE(h)
$289 $273 
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSMarch 29,
2026		March 30,
2025
BIOPHARMA(a)
$14,161 $13,441 
PFIZER U.S. COMMERCIAL DIVISION
7,686 7,572 
PFIZER INTERNATIONAL COMMERCIAL DIVISION
5,233 4,849 
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(i)
1,242 1,020 
Total Alliance revenues included above$2,339 $2,113 
Total Royalty revenues included above
$396 $308 
(a)In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation.
(b)Reflects alliance revenues and royalty revenues.
(c)Primarily reflects alliance revenues and royalty revenues.
(d)Reflects product revenues and royalty revenues.
(e)Erbitux® is a registered trademark of ImClone LLC.
(f)Reflects alliance revenues.
(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Zirabev, Retacrit, Trazimera and Nivestym.
(h)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in both periods presented. We reclassified prior period amounts to conform to the current period presentation.
(i)See Note 13A above.
v3.26.1
Basis of Presentation and Significant Accounting Policies - Narrative (Details)
 3 Months Ended
Mar. 29, 2026
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 2
Number of reportable segments 1
v3.26.1
Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Schedule Of Accrued Liabilities [Line Items]    
Total accrued rebates and other sales-related accruals $ 11,550 $ 11,666
Trade accounts receivable, less allowance for doubtful accounts [Member]    
Schedule Of Accrued Liabilities [Line Items]    
Total accrued rebates and other sales-related accruals 1,699 1,803
Other current liabilities [Member]    
Schedule Of Accrued Liabilities [Line Items]    
Accrued rebates 8,846 7,909
Other accruals 718 750
Other noncurrent liabilities [Member]    
Schedule Of Accrued Liabilities [Line Items]    
Total accrued rebates and other sales-related accruals $ 287 $ 1,204
v3.26.1
Acquisition, In-Licensing Arrangement and Sale of Investment - Acquisitions Narrative (Details)
$ / shares in Units, $ in Millions
Nov. 13, 2025
USD ($)
payment
$ / shares
Mar. 29, 2026
USD ($)
Dec. 31, 2025
USD ($)
Business Combination [Line Items]      
Goodwill   $ 71,409 $ 71,264
Metsera [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 65.60    
Payments to acquire business, gross $ 8,000    
Acquisitions of businesses, net of cash acquired $ 7,800    
Number of milestone payments | payment 3    
Noncash contingent value right $ 632    
Stock awards related to pre-acquisition services 475    
Identifiable intangible asset, net 8,000    
Goodwill 2,000    
Net deferred tax liabilities 1,600    
Contingent consideration liabilities $ 672    
Metsera [Member] | Total Payments to Former Metsera Shareholders [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 20.65    
Contingent value right $ 2,300    
Metsera [Member] | Phase 3 Clinical Trial [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 4.60    
Metsera [Member] | FDA Approval of MET-097i [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares 6.40    
Metsera [Member] | FDA Approval of MET-097i + MET-233i [Member]      
Business Combination [Line Items]      
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 9.65    
v3.26.1
Acquisition and In-Licensing Arrangement - In-Licensing Arrangement (Details)
$ in Millions
 1 Months Ended
Feb. 28, 2026
USD ($)
Sciwind Biosciences | In-Licensing Agreement [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Upfront, regulatory and sales milestone payments $ 495
v3.26.1
Acquisition, In-Licensing Arrangement and Sale of Investment - Sale of Investment (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2026
Mar. 29, 2026
Mar. 30, 2025
Mar. 30, 2026
Dec. 31, 2025
Schedule of Equity Method Investments [Line Items]          
Equity-method investments   $ 237     $ 235
Gain on sale of investment   $ 0 $ 6,311    
ViiV [Member] | Subsequent Event [Member]          
Schedule of Equity Method Investments [Line Items]          
Equity method investment, ownership percentage       11.70%  
Equity-method investments $ 0        
Gain on sale of investment $ 1,875        
v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 24 Months Ended 30 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Mar. 29, 2026
Mar. 29, 2026
Restructuring Cost and Reserve [Line Items]        
Restructuring charges [1] $ 49 $ 621    
Productivity and Operational Efficiencies [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 6      
Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 31 617    
Realigning Our Cost Base Program [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 5,300   $ 5,300 $ 5,300
Restructuring cost incurred to date 4,300   4,300 4,300
Realigning Our Cost Base Program [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 3,700   3,700 3,700
Restructuring cost incurred to date 3,300   3,300 3,300
Restructuring charges 47 587   2,900
Realigning Our Cost Base Program - Initial Phase [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 4,700   4,700 4,700
Realigning Our Cost Base Program - Initial Phase [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 3,100   3,100 3,100
Realigning Our Cost Base Program - Research and Development [Member] | Biopharma [Member] | Productivity and Operational Efficiencies [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost 600   600 600
Manufacturing Optimization Program [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring cost incurred to date 1,100   1,100 1,100
Restructuring charges (22) $ (4) 853  
Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member]        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost $ 1,400   $ 1,400 $ 1,400
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
 3 Months Ended 24 Months Ended 30 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Mar. 29, 2026
Mar. 29, 2026
Restructuring charges/(credits):        
Employee terminations $ 15 $ 384    
Asset impairments 28 173    
Exit costs 6 64    
Restructuring charges/(credits) [1] 49 621    
Integration costs and other [2] 51 57    
Restructuring charges and certain acquisition-related costs 100 678    
Additional depreciation––asset restructuring recorded in Cost of sales [3] 3 4    
Implementation costs [4] 89 50    
Total costs associated with acquisitions and cost-reduction/productivity initiatives 195 673    
Biopharma [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) 31 617    
Biopharma [Member] | Manufacturing Optimization Program [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) (22) (4) $ 853  
Biopharma [Member] | Realigning Our Cost Base Program [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) 47 587   $ 2,900
Other (income)/deductions––net [Member]        
Restructuring charges/(credits):        
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net 3 (59)    
Cost of sales [Member]        
Restructuring charges/(credits):        
Implementation costs [4] 15 20    
Selling, informational and administrative expenses [Member]        
Restructuring charges/(credits):        
Implementation costs [4] 36 6    
Research and development expenses [Member]        
Restructuring charges/(credits):        
Implementation costs [4] $ 38 $ 24    
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
[2] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[3] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[4] Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] $ 1,910  
Provision [2] 49 $ 621
Utilization and other [3] (371)  
Balance, ending [4] 1,588  
Other Current Liabilities [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning 1,400  
Balance, ending 1,200  
Other Noncurrent Liabilities [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning 466  
Balance, ending 431  
Employee Termination Costs [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] 1,783  
Provision 15  
Utilization and other [3] (330)  
Balance, ending [4] 1,467  
Asset Impairment Charges [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] 0  
Provision 28  
Utilization and other [3] (28)  
Balance, ending [4] 0  
Exit Costs [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] 127  
Provision 6  
Utilization and other [3] (12)  
Balance, ending [4] $ 121  
[1] Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
[3] Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
[4] Included in Other current liabilities ($1.2 billion) and Other noncurrent liabilities ($431 million).
v3.26.1
Other (Income)/Deductions—Net - Schedule of Other (Income)/Deductions—Net (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Other Income and Expenses [Abstract]    
Interest income $ (115) $ (143)
Interest expense 668 654
Net interest expense 554 511
Net (gains)/losses recognized during the period on equity securities [1] 9 370
Net periodic benefit costs/(credits) other than service costs (72) (158)
Certain legal matters, net [2] 191 142
Certain asset impairments [3] 0 224
Changes in fair value of contingent consideration liabilities [4] 295 8
Other, net (116) (144)
Other (income)/deductions––net $ 861 $ 953
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The amount for the first quarter of 2026 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2025 included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
[3] The amount for the first quarter of 2025 primarily represented an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
[4] See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.
v3.26.1
Other (Income)/Deductions—Net - Footnotes (Detail)
$ in Millions
 3 Months Ended
Mar. 30, 2025
USD ($)
IPR&D [Member]  
Loss Contingencies [Line Items]  
Intangible asset impairment charge $ 210
v3.26.1
Tax Matters - Narrative (Detail) - USD ($)
$ in Billions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Income Tax Disclosure [Abstract]    
Effective tax rate for income from continuing operations 14.60% (6.80%)
Repatriation tax liability $ 15  
v3.26.1
Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Income Tax Disclosure [Abstract]    
Foreign currency translation adjustments, net [1] $ 76 $ (102)
Unrealized holding gains/(losses) on derivative financial instruments, net (5) (34)
Reclassification adjustments for (gains)/losses included in net income 6 (55)
Derivatives qualifying as hedges, tax, total 0 (89)
Unrealized holding gains/(losses) on available-for-sale securities, net 5 (4)
Reclassification adjustments for (gains)/losses included in net income 3 19
Available-for-sale securities, tax, total 7 15
Reclassification adjustments related to amortization of prior service costs and other, net (2) (7)
Reclassification adjustments related to curtailments of prior service costs and other, net (1) (9)
Pension and other postretirement benefit plans, net prior service cost (credit), tax (3) (16)
Tax provision/(benefit) on other comprehensive income/(loss) $ 81 $ (191)
[1] Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
v3.26.1
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 86,775 $ 88,497
Other comprehensive income/(loss), net of tax 863 (741)
Ending balance 90,404 90,637
Accumulated Other Comprehensive Income (Loss) [Member]    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (8,069) (7,842)
Other comprehensive income/(loss), net of tax 867 [1] (738)
Ending balance (7,203) $ (8,581)
Foreign Currency Translation Adjustment [Member]    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance [2] (7,796)  
Other comprehensive income/(loss), net of tax [1],[2] 851  
Ending balance [2] (6,944)  
Derivative Financial Instruments [Member]    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (321)  
Other comprehensive income/(loss), net of tax [1] (27)  
Ending balance (348)  
Available-For-Sale Securities [Member]    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (28)  
Other comprehensive income/(loss), net of tax [1] 52  
Ending balance 24  
Prior Service (Costs)/Credits and Other [Member]    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 75  
Other comprehensive income/(loss), net of tax [1] (9)  
Ending balance $ 66  
[1] Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.
[2] Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
v3.26.1
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values $ 1,865 $ 2,596
Current derivative assets 504 416
Noncurrent derivative assets 155 116
Insurance contracts [1] 950 999
Total other noncurrent assets 1,105 1,115
Total assets 12,315 13,953
Contingent consideration liabilities [2] 95 95
Total other current liabilities 379 523
Contingent consideration liabilities [2] 1,946 1,695
Total other noncurrent liabilities 3,027 2,725
Total liabilities 3,406 3,248
Long-term equity securities held in trust 147 146
Interest rate contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 6 0
Noncurrent derivative assets 27 52
Current derivative liabilities 1 16
Noncurrent derivative liabilities 275 215
Foreign exchange contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 498 416
Noncurrent derivative assets 128 64
Current derivative liabilities 283 412
Noncurrent derivative liabilities 807 815
Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [3] 1,865 2,596
Available-for-sale debt securities 8,189 9,183
Total short-term investments 10,054 11,779
Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [4] 653 642
Available-for-sale debt securities 0 1
Total long-term investments 653 642
Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Insurance contracts [1] 0 0
Total other noncurrent assets 0 0
Total assets 653 642
Contingent consideration liabilities [2] 0 0
Total other current liabilities 0 0
Contingent consideration liabilities [2] 0 0
Total other noncurrent liabilities 0 0
Total liabilities 0 0
Level 1 [Member] | Interest rate contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Current derivative liabilities 0 0
Noncurrent derivative liabilities 0 0
Level 1 [Member] | Foreign exchange contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Current derivative liabilities 0 0
Noncurrent derivative liabilities 0 0
Level 1 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [3] 0 0
Available-for-sale debt securities 0 0
Total short-term investments 0 0
Level 1 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [4] 653 642
Available-for-sale debt securities 0 0
Total long-term investments 653 642
Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 504 416
Noncurrent derivative assets 155 116
Insurance contracts [1] 950 999
Total other noncurrent assets 1,105 1,115
Total assets 11,663 13,311
Contingent consideration liabilities [2] 0 0
Total other current liabilities 284 428
Contingent consideration liabilities [2] 0 0
Total other noncurrent liabilities 1,081 1,030
Total liabilities 1,365 1,458
Level 2 [Member] | Interest rate contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 6 0
Noncurrent derivative assets 27 52
Current derivative liabilities 1 16
Noncurrent derivative liabilities 275 215
Level 2 [Member] | Foreign exchange contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 498 416
Noncurrent derivative assets 128 64
Current derivative liabilities 283 412
Noncurrent derivative liabilities 807 815
Level 2 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [3] 1,865 2,596
Available-for-sale debt securities 8,189 9,183
Total short-term investments 10,054 11,779
Level 2 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [4] 0 0
Available-for-sale debt securities 0 1
Total long-term investments 0 1
Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Insurance contracts [1] 0 0
Total other noncurrent assets 0 0
Total assets 0 0
Contingent consideration liabilities [2] 95 95
Total other current liabilities 95 95
Contingent consideration liabilities [2] 1,946 1,695
Total other noncurrent liabilities 1,946 1,695
Total liabilities 2,041 1,790
Level 3 [Member] | Interest rate contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Current derivative liabilities 0 0
Noncurrent derivative liabilities 0 0
Level 3 [Member] | Foreign exchange contracts [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current derivative assets 0 0
Noncurrent derivative assets 0 0
Current derivative liabilities 0 0
Noncurrent derivative liabilities 0 0
Level 3 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [3] 0 0
Available-for-sale debt securities 0 0
Total short-term investments 0 0
Level 3 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities with readily determinable fair values [4] 0 0
Available-for-sale debt securities 0 0
Total long-term investments 0 0
Government and agency—non-U.S. [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 3,888 4,859
Government and agency—non-U.S. [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 3,888 4,859
Government and agency—non-U.S. [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 1
Government and agency—non-U.S. [Member] | Level 1 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Government and agency—non-U.S. [Member] | Level 1 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Government and agency—non-U.S. [Member] | Level 2 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 3,888 4,859
Government and agency—non-U.S. [Member] | Level 2 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 1
Government and agency—non-U.S. [Member] | Level 3 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Government and agency—non-U.S. [Member] | Level 3 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Government and agency—U.S. [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 2,935 3,030
Government and agency—U.S. [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 2,935 3,030
Government and agency—U.S. [Member] | Level 1 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Government and agency—U.S. [Member] | Level 2 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 2,935 3,030
Government and agency—U.S. [Member] | Level 3 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Corporate and other [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 1,366 1,294
Corporate and other [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 1,366 1,294
Corporate and other [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Corporate and other [Member] | Level 1 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Corporate and other [Member] | Level 2 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 1,366 1,294
Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Corporate and other [Member] | Level 3 [Member] | Short-term investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities 0 0
Corporate and other [Member] | Level 3 [Member] | Long-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale debt securities $ 0 $ 0
[1] Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).
[2] Includes the fair value of contingent consideration associated with the acquisition of Metsera and certain prior business combinations. Fair value is estimated by using a probability-weighted discounted cash flow approach (see Notes 1D and 16D in our 2025 Form 10-K and Note 2A for additional information on contingent consideration liabilities).
[3] Includes money market funds primarily invested in U.S. Treasury and government debt.
[4] Long-term equity securities of $147 million as of March 29, 2026 and $146 million as of December 31, 2025 were held in restricted trusts for U.S. non-qualified employee benefit plans.
v3.26.1
Financial Instruments - Schedule of Changes in Contingent Consideration Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value, beginning $ 1,790 $ 517
Changes in estimated fair value [1] 295 8
Additions 0 0
Settlements and other (45) (48)
Transfer into/(out of) Level 3 0 0
Fair value, ending $ 2,041 $ 477
[1] Reported in Other (income)/deductions––net. See Note 4. The amount in the first quarter of 2026 is primarily related to our acquisition of Metsera.
v3.26.1
Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Billions
Mar. 29, 2026
Dec. 31, 2025
Carrying Value [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value $ 61 $ 62
Estimated Fair Value [Member] | Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value $ 58 $ 60
v3.26.1
Financial Instruments - Investments by Classification Type (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Short-term investments    
Equity securities with readily determinable fair values $ 1,865 $ 2,596
Available-for-sale debt securities 8,189 9,183
Held-to-maturity debt securities 1,318 675
Total Short-term investments 11,372 12,454
Long-term investments    
Equity securities with readily determinable fair values 653 642
Available-for-sale debt securities 0 1
Held-to-maturity debt securities 47 48
Private equity securities at cost [1] 688 696
Equity-method investments 237 235
Total Long-term investments $ 1,626 $ 1,621
[1] Represent investments in the life sciences sector
v3.26.1
Financial Instruments - Schedule of Investment Securities (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]    
Debt securities, amortized cost $ 9,526 $ 9,938
Debt securities, gross unrealized gains 29 3
Debt securities, gross unrealized losses (2) (35)
Debt securities, fair value 9,554 9,906
Debt securities maturities, within 1 year, fair value 9,507  
Debt securities maturities, over 1 to 5 years, fair value 10  
Debt securities maturities, over 5 years, fair value 38  
Corporate, Time Deposits and Other [Member]    
Debt Securities, Held-to-maturity, Maturity [Abstract]    
Held-to-maturity securities, amortized cost 756 487
Held-to-maturity securities, gross unrealized gains 0 0
Held-to-maturity securities, gross unrealized losses 0 0
Held-to-maturity securities, fair value 756 487
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]    
Held-to-maturity securities, debt maturities, within 1 year, fair value 710  
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value 9  
Held-to-maturity securities, debt maturities, over 5 years, fair value 37  
Government and agency—non-U.S. [Member]    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Available-for-sale debt securities, amortized cost 3,860 4,890
Available-for-sale debt securities, gross unrealized gains 29 3
Available-for-sale debt securities, gross unrealized losses (2) (34)
Available-for-sale debt securities, fair value 3,888 4,859
Available-for-sale Securities, Debt Maturities [Abstract]    
Available-for-sale securities, debt maturities, within 1 year, fair value 3,888  
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value 0  
Available-for-sale securities, debt maturities, over 5 years, fair value 0  
Debt Securities, Held-to-maturity, Maturity [Abstract]    
Held-to-maturity securities, amortized cost 610 236
Held-to-maturity securities, gross unrealized gains 0 0
Held-to-maturity securities, gross unrealized losses 0 0
Held-to-maturity securities, fair value 610 236
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]    
Held-to-maturity securities, debt maturities, within 1 year, fair value 608  
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value 0  
Held-to-maturity securities, debt maturities, over 5 years, fair value 1  
Government and agency—U.S. [Member]    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Available-for-sale debt securities, amortized cost 2,935 3,030
Available-for-sale debt securities, gross unrealized gains 0 0
Available-for-sale debt securities, gross unrealized losses 0 0
Available-for-sale debt securities, fair value 2,935 3,030
Available-for-sale Securities, Debt Maturities [Abstract]    
Available-for-sale securities, debt maturities, within 1 year, fair value 2,935  
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value 0  
Available-for-sale securities, debt maturities, over 5 years, fair value 0  
Corporate and other [Member]    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Available-for-sale debt securities, amortized cost 1,366 1,295
Available-for-sale debt securities, gross unrealized gains 0 0
Available-for-sale debt securities, gross unrealized losses 0 (1)
Available-for-sale debt securities, fair value 1,366 $ 1,294
Available-for-sale Securities, Debt Maturities [Abstract]    
Available-for-sale securities, debt maturities, within 1 year, fair value 1,366  
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value 0  
Available-for-sale securities, debt maturities, over 5 years, fair value $ 0  
v3.26.1
Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Fair Value Disclosures [Abstract]    
Net (gains)/losses recognized during the period on equity securities [1] $ 9 $ 370
Less: Net (gains)/losses recognized during the period on equity securities sold during the period (6) (924)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date $ 15 $ 1,295
[1] Reported in Other (income)/deductions––net. See Note 4.
v3.26.1
Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)
$ in Millions
Mar. 29, 2026
USD ($)
Fair Value Disclosures [Abstract]  
Cumulative impairment losses and downward price adjustments on equity securities $ 444
Cumulative upward price adjustments on equity securities $ 225
v3.26.1
Financial Instruments - Short-term Borrowings (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Fair Value Disclosures [Abstract]    
Current portion of long-term debt, principal amount $ 3,864 $ 3,000
Other short-term borrowings, principal amount [1] 29 157
Total short-term borrowings, principal amount 3,893 3,157
Net unamortized discounts, premiums and debt issuance costs (3) (3)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted $ 3,890 $ 3,154
[1] Primarily includes cash collateral. See Note 7F.
v3.26.1
Financial Instruments - Long-Term Debt (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Debt Instrument [Line Items]    
Net unamortized discounts, premiums and debt issuance costs $ (3) $ (3)
Total long-term debt, carried at historical proceeds, as adjusted 60,565 61,641
Unsecured Debt [Member]    
Debt Instrument [Line Items]    
Total long-term debt, principal amount 60,313 61,293
Net fair value adjustments related to hedging and purchase accounting 726 834
Net unamortized discounts, premiums and debt issuance costs (473) (486)
Total long-term debt, carried at historical proceeds, as adjusted $ 60,565 $ 61,641
v3.26.1
Financial Instruments - Derivative Narrative (Details)
 3 Months Ended
Mar. 29, 2026
Foreign exchange contracts [Member]  
Derivative [Line Items]  
Derivative term of contract 2 years
v3.26.1
Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Derivative [Line Items]    
Asset $ 659 $ 532
Liability 1,365 1,458
Derivatives designated as hedging instruments [Member]    
Derivative [Line Items]    
Asset 550 377
Liability 1,218 1,296
Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]    
Derivative [Line Items]    
Notional [1] 23,593 22,984
Asset [1] 517 325
Liability [1] 942 1,066
Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]    
Derivative [Line Items]    
Notional 7,995 6,750
Asset 33 52
Liability 276 230
Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]    
Derivative [Line Items]    
Notional 17,134 22,777
Asset 109 155
Liability 147 162
Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]    
Derivative [Line Items]    
Notional $ 4,900 $ 5,000
[1] The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of March 29, 2026 and $5.0 billion as of December 31, 2025.
v3.26.1
Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Amount of Gains/(Losses) Recognized in OID [1] $ (13) $ (31)
Derivative, Amount of Gains/(Losses), Cash Flow Hedge, Recognized in OCI (36) (123)
Amount of Gains/(Losses) Recognized in OCI [1] 267 (517)
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [2] (9) 313
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1] 44 354
Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Non-Derivative, Amount of Gains/(Losses) Recognized in OCI [1],[3] (2) (31)
Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1],[3] 0 0
Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Non-Derivative, Amount of Gains/(Losses) Recognized in OCI [1],[3] 18 0
Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1],[3] 0 0
Derivative Financial Instruments Not Designated as Hedges [Member] | Foreign exchange contracts [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Amount of Gains/(Losses) Recognized in OID [1] (13) (31)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Amount of Gains/(Losses), Cash Flow Hedge, Recognized in OCI [1] 0 0
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1] 0 2
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Amount of Gains/(Losses), Cash Flow Hedge, Recognized in OCI [1],[4] (48) (138)
Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings [1],[5] 12 15
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1],[4] (21) 295
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing [1],[5] 12 16
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Amount of Gains/(Losses), Fair Value Hedge, Recognized in OID [1] (85) 142
Derivative, Amount of Gains/(Losses), Hedged Item, Recognized in OID [1] 85 (142)
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings [1],[5] 47 75
Derivative, Amount of Gains/(Losses), Net Investment Hedge, Recognized in OCI [1] 240 (437)
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing [1],[5] 53 41
Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS [1] $ 0 $ 0
[1] OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income/(loss).
[2] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[3] Long-term debt includes foreign currency borrowings, which are used in net investment hedges; the related carrying values as of March 29, 2026 and December 31, 2025 were $863 million and $879 million, respectively.
[4] The amounts reclassified from OCI into COS were a net loss of $14 million in the first quarter of 2026 and a net gain of $62 million in the first quarter of 2025. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $9 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 17 years and relates to foreign currency debt.
[5] The amounts reclassified from OCI were reclassified into OID.
v3.26.1
Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Dec. 31, 2025
Derivative [Line Items]      
(Loss) gain reclassified from OCI into COS [1] $ (9) $ 313  
Foreign currency long-term debt [Member]      
Derivative [Line Items]      
Long-term debt 863   $ 879
Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]      
Derivative [Line Items]      
Pre-tax loss expected to be reclassified within the next 12 months $ (9)    
Remaining period of hedging exposure 17 years    
Designated as Hedging Instrument [Member] | Cost of sales [Member] | Foreign exchange contracts [Member]      
Derivative [Line Items]      
(Loss) gain reclassified from OCI into COS $ (14) $ 62  
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
v3.26.1
Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Fair Value Disclosures [Abstract]    
Carrying Amount of Hedged Assets/Liabilities [1] $ 8,429 $ 7,110
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability (248) (163)
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability $ 803 $ 821
[1] Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
v3.26.1
Financial Instruments - Credit Risk (Details)
$ in Millions
Mar. 29, 2026
USD ($)
Fair Value Disclosures [Abstract]  
Derivatives in a net payable position $ 1,100
Collateral posted 1,200
Derivatives in a net receivable position 41
Collateral received $ 29
v3.26.1
Other Financial Information - Inventories (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Other Financial Information [Abstract]    
Finished goods $ 4,031 $ 4,113
Work-in-process 5,713 5,634
Raw materials and supplies 923 907
Inventories 10,667 10,654
Noncurrent inventories not included above [1] $ 2,462 $ 2,370
[1] Included in Other noncurrent assets. Based on our current estimates and assumptions, there are no recoverability issues for these amounts.
v3.26.1
Other Financial Information - Supplier Finance Program Obligation (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Other Financial Information [Abstract]    
Supplier finance program payable $ 518 $ 574
v3.26.1
Identifiable Intangible Assets, Net and Goodwill - Schedule of Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount $ 104,780 $ 104,006
Finite-lived intangible assets, accumulated amortization (73,862) (72,496)
Finite-lived intangible assets, net 30,918 31,510
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 21,641 22,221
Intangible assets, gross carrying amount 126,421 126,227
Finite-lived intangible assets, accumulated amortization (73,862) (72,496)
Identifiable Intangible Assets, less Accumulated Amortization 52,559 53,731
IPR&D [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets [1] 21,180 21,760
License Agreements and Other [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 460 460
Developed technology rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount [1] 101,396 100,630
Finite-lived intangible assets, accumulated amortization [1] (71,491) (70,172)
Finite-lived intangible assets, net [1] 29,905 30,458
Indefinite-lived Intangible Assets [Line Items]    
Finite-lived intangible assets, accumulated amortization [1] (71,491) (70,172)
Brands [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 1,035 1,035
Finite-lived intangible assets, accumulated amortization (1,035) (1,035)
Finite-lived intangible assets, net 0 0
Indefinite-lived Intangible Assets [Line Items]    
Finite-lived intangible assets, accumulated amortization (1,035) (1,035)
License Agreements and Other [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 2,350 2,341
Finite-lived intangible assets, accumulated amortization (1,336) (1,289)
Finite-lived intangible assets, net 1,013 1,052
Indefinite-lived Intangible Assets [Line Items]    
Finite-lived intangible assets, accumulated amortization $ (1,336) $ (1,289)
[1] The gross carrying amounts reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).
v3.26.1
Identifiable Intangible Assets, Net and Goodwill - Footnotes (Details) - Tukysa [Member]
$ in Millions
 3 Months Ended
Mar. 29, 2026
USD ($)
Developed technology rights [Member]  
Indefinite-lived Intangible Assets [Line Items]  
Finite-lived intangible assets, period increase $ 580
IPR&D [Member]  
Indefinite-lived Intangible Assets [Line Items]  
Indefinite-lived intangible assets, period increase (decrease) $ (580)
v3.26.1
Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Pension Plan [Member] | U.S. [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 0 $ 0
Interest cost 127 133
Expected return on plan assets (188) (184)
Amortization of prior service cost/(credit) 0 0
Actuarial (gains)/losses 0 0
Curtailments 0 0
Special termination benefits 0 0
Net periodic benefit cost/(credit) reported in income (60) (51)
Pension Plan [Member] | International [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 24 24
Interest cost 75 70
Expected return on plan assets (82) (79)
Amortization of prior service cost/(credit) 1 1
Actuarial (gains)/losses 8 0
Curtailments 3 (9)
Special termination benefits 5 0
Net periodic benefit cost/(credit) reported in income 34 8
Postretirement Plans [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 4 4
Interest cost 7 6
Expected return on plan assets (16) (14)
Amortization of prior service cost/(credit) (8) (32)
Actuarial (gains)/losses 0 0
Curtailments (5) (50)
Special termination benefits 0 0
Net periodic benefit cost/(credit) reported in income $ (18) $ (85)
v3.26.1
Pension and Postretirement Benefit Plans - Narrative (Detail) - Pension Plan [Member]
$ in Millions
 3 Months Ended
Mar. 29, 2026
USD ($)
U.S. [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Contributions by employer $ 63
International [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Contributions by employer $ 68
v3.26.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
EPS Numerator    
Income from continuing operations attributable to Pfizer Inc. common shareholders $ 2,701 $ 2,967
Income from continuing operations attributable to Pfizer Inc. common shareholders 2,701 2,967
Discontinued operations––net of tax (13) 0
Net income attributable to Pfizer Inc. common shareholders 2,687 2,967
Net income attributable to Pfizer Inc. common shareholders $ 2,687 $ 2,967
EPS Denominator    
Weighted-average number of common shares outstanding––Basic (in shares) 5,691 5,675
Common-share equivalents (in shares) 40 36
Weighted-average number of common shares outstanding––Diluted (in shares) 5,731 5,710
Anti-dilutive common stock equivalents (in shares) [1] 11 17
[1] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
v3.26.1
Contingencies and Certain Commitments - Patent Litigation (Details)
$ in Millions
 1 Months Ended
Apr. 30, 2026
case
Mar. 29, 2026
USD ($)
patent
Jul. 31, 2025
patent
Mar. 30, 2025
patent
Aug. 31, 2024
patent
Jul. 31, 2024
patent
Apr. 30, 2024
patent
Mar. 31, 2024
patent
Nov. 30, 2023
patent
Apr. 30, 2023
patent
Sep. 30, 2022
patent
Aug. 31, 2022
patent
Gain Contingencies [Line Items]                        
Threshold for disclosure of proceedings under environmental laws | $   $ 1                    
Vyndaqel Litigation Case [Member] | Subsequent Event [Member]                        
Gain Contingencies [Line Items]                        
Number of cases settled | case 3                      
Micro Labs, Changzhou and Biocon Patent Infringement Case [Member]                        
Gain Contingencies [Line Items]                        
Number of patents being challenged   3                    
Comirnaty [Member] | ModernaTX U.S. Patent Infringement Case [Member]                        
Gain Contingencies [Line Items]                        
Loss contingency, number of patents allegedly infringed upon                       3
Loss contingency, patents under review               2        
Loss contingency, patents ruled invalid       2                
Comirnaty [Member] | ModernaTX European Patent Infringement Case [Member]                        
Gain Contingencies [Line Items]                        
Loss contingency, number of patents allegedly infringed upon                     2 2
Loss contingency, patents allegedly infringed and subsequently revoked                 1      
Loss contingency, patents ruled invalid and subsequently revoked           1            
Comirnaty [Member] | Arbutus and Genevant U.S. Patent Infringement Case [Member]                        
Gain Contingencies [Line Items]                        
Loss contingency, number of patents allegedly infringed upon                   5    
Comirnaty [Member] | GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]                        
Gain Contingencies [Line Items]                        
Loss contingency, number of patents allegedly infringed upon         3   5          
Comirnaty [Member] | GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Patent Infringement Case [Member]                        
Gain Contingencies [Line Items]                        
Loss contingency, number of patents allegedly infringed upon     3                  
Comirnaty [Member] | GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case [Member]                        
Gain Contingencies [Line Items]                        
Loss contingency, number of patents allegedly infringed upon     2                  
v3.26.1
Contingencies and Certain Commitments - Product Litigation, Commercial and Other Matters, Legal Proceedings (Details)
Dec. 31, 2020
complaint
Pending Litigation [Member] | Greenstone Antitrust Litigation [Member]  
Loss Contingencies [Line Items]  
Number of complaints 2
v3.26.1
Segment, Geographic and Other Revenue Information - Narrative (Detail)
$ in Millions
 3 Months Ended
Mar. 29, 2026
USD ($)
segment
Dec. 31, 2025
USD ($)
Segment Reporting Information [Line Items]    
Number of operating segments | segment 2  
Number of reportable segments | segment 1  
Total assets $ 207,618 $ 208,160
Comirnaty [Member]    
Segment Reporting Information [Line Items]    
Remaining performance obligation 2,100  
Paxlovid [Member]    
Segment Reporting Information [Line Items]    
Remaining performance obligation 948  
Government and Government Sponsored [Member] | Paxlovid and Comirnaty [Member]    
Segment Reporting Information [Line Items]    
Deferred revenues 1,500 1,500
Deferred revenues, current 646 689
Deferred revenues, noncurrent 816 $ 826
Deferred revenue recognized $ 58  
v3.26.1
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Segment Reporting Information [Line Items]    
Revenues: $ 14,451 $ 13,715
Earnings [1] 3,170 2,785
Depreciation and Amortization [2] 1,613 1,618
Other Business Activities [Member]    
Segment Reporting Information [Line Items]    
Revenues: [3] 289 273
Earnings [1],[3] (1,668) (1,384)
Depreciation and Amortization [2],[3] 78 74
Reconciling Items [Member] | Amortization of Intangible Assets [Member]    
Segment Reporting Information [Line Items]    
Earnings [1] (1,183) (1,211)
Depreciation and Amortization [2] 1,183 1,211
Reconciling Items [Member] | Acquisition-Related Items [Member]    
Segment Reporting Information [Line Items]    
Earnings [1] (504) (282)
Depreciation and Amortization [2] 0 (1)
Reconciling Items [Member] | Certain Significant Items [Member]    
Segment Reporting Information [Line Items]    
Earnings [1],[4] (312) (1,407)
Depreciation and Amortization [2],[4] 3 4
Biopharma [Member]    
Segment Reporting Information [Line Items]    
Revenues: [5] 14,161 13,441
Earnings 6,838 7,069
Biopharma [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Revenues: [6] 14,161 13,441
Earnings [1],[6] 6,838 7,069
Depreciation and Amortization [2],[6] $ 348 $ 331
[1] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
[2] Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.
[3] Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.
[4] Earnings in the first quarter of 2025 included, among other items restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $666 million (primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 3.
[5] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation
[6] Biopharma’s earnings include dividend income from our investment in ViiV of $82 million in the first quarter of 2026 and $39 million in the first quarter of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the first quarter of 2025 also reflected a credit to Cost of Sales representing a favorable revision of our estimate of accrued royalties.
v3.26.1
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment - Footnotes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income [1] $ 3,170 $ 2,785
Restructuring charges   666
Biopharma [Member]    
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income 6,838 7,069
Biopharma [Member] | ViiV [Member]    
Segment Reporting Information [Line Items]    
Dividend income (82) (39)
Other Business Activities [Member]    
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income [1],[2] $ (1,668) (1,384)
Other Business Activities [Member] | Reclassification Other [Member]    
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income   $ 36
[1] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
[2] Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.
v3.26.1
Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Segment Reporting Information [Line Items]    
Revenues: $ 14,451 $ 13,715
Cost of sales [1] 3,548 2,845
Selling, informational and administrative expenses [1] 2,961 3,031
Research and development expenses [1] 2,490 2,203
Acquired in-process research and development expenses 137 9
Other (income)/deductions––net 861 953
Income from continuing operations before provision/(benefit) for taxes on income [2] 3,170 2,785
Biopharma [Member]    
Segment Reporting Information [Line Items]    
Revenues: [3] 14,161 13,441
Cost of sales 3,034 2,314
Selling, informational and administrative expenses 2,131 2,186
Research and development expenses 2,137 1,941
Acquired in-process research and development expenses 137 9
Other (income)/deductions––net (116) (78)
Income from continuing operations before provision/(benefit) for taxes on income $ 6,838 $ 7,069
[1] Exclusive of amortization of intangible assets.
[2] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
[3] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation
v3.26.1
Segment, Geographic and Other Revenue Information - Revenues by Geographic Area (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues: $ 14,451 $ 13,715
U.S. [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues: 8,731 8,374
International Developed Markets [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues: 3,426 3,178
International Emerging Markets [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues: $ 2,293 $ 2,163
v3.26.1
Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Revenue from External Customer [Line Items]    
Revenues: $ 14,451 $ 13,715
Alliance revenues 2,339 2,113
Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [1] 14,161 13,441
Biopharma [Member] | U.S. Commercial Division [Member]    
Revenue from External Customer [Line Items]    
Revenues: 7,686 7,572
Biopharma [Member] | International Commercial Division [Member]    
Revenue from External Customer [Line Items]    
Revenues: 5,233 4,849
Biopharma [Member] | Global Hospital and Biosimilars Division [Member]    
Revenue from External Customer [Line Items]    
Revenues: [2] 1,242 1,020
Pfizer CentreOne [Member]    
Revenue from External Customer [Line Items]    
Revenues: [3] 289 273
Total Alliance revenues [Member]    
Revenue from External Customer [Line Items]    
Alliance revenues 2,339 2,113
Royalty [Member]    
Revenue from External Customer [Line Items]    
Royalty revenue 396 308
Primary Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 5,542 5,692
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [4] 2,166 1,923
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 1,690 1,660
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 353 248
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 232 565
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 186 491
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 180 131
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 81 63
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 654 609
Specialty Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 2,939 2,616
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 1,602 1,486
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 180 128
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 150 135
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 138 140
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 122 88
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 93 95
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 76 58
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 579 486
Oncology [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 3,826 3,494
Oncology [Member] | Ibrance [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 1,008 977
Oncology [Member] | Padcev [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 591 426
Oncology [Member] | Xtandi [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [5] 444 458
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 305 222
Oncology [Member] | Inlyta [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 214 219
Oncology [Member] | Adcetris [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [6] 190 218
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [7] 174 136
Oncology [Member] | Bosulif [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 129 151
Oncology [Member] | Tukysa [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 122 102
Oncology [Member] | Orgovyx [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [8] 109 76
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 80 60
Oncology [Member] | Talzenna [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 50 40
Oncology [Member] | Tivdak [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 33 33
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 376 377
Hospital and Biosimilars [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [1] 1,854 1,639
Hospital and Biosimilars [Member] | Oncology Biosimilars [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [9] 409 264
Hospital and Biosimilars [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 199 164
Hospital and Biosimilars [Member] | Inflectra [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 182 153
Hospital and Biosimilars [Member] | Zithromax [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 112 158
Hospital and Biosimilars [Member] | All Other Hospital and Biosimilars [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: $ 953 $ 901
[1] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation
[2] See Note 13A above.
[3] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in both periods presented. We reclassified prior period amounts to conform to the current period presentation.
[4]
(b)Reflects alliance revenues and royalty revenues.
[5] Primarily reflects alliance revenues and royalty revenues.
[6] Reflects product revenues and royalty revenues.
[7] Erbitux® is a registered trademark of ImClone LLC.
[8] Reflects alliance revenues.
[9] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Zirabev, Retacrit, Trazimera and Nivestym.